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Abstract
Uric acid has a long history in clinical analysis and it has served as an 
important diagnostic within a number of different contexts. The increasing interest 
in metabolic syndrome has led to uric acid being used in combination with a 
number of other biomarkers in the assessment of cardiovascular risk. The 
traditional view of uric acid as principally an interferent in electrochemical 
measurement is now gradually being replaced with the realization that its 
measurement could serve as an invaluable secondary (if not primary) marker 
when monitoring conditions such as diabetes and heart disease.
Rather than attempting to wholly exclude uric acid electrochemistry, many 
strategies are being developed that can integrate the uric acid signal within the 
device architecture, such that a range of biomarkers can be sequentially 
assessed. This thesis describes the development and characterization of two 
main strategies to incorporate uric acid electrochemistry alongside other 
biomarkers: a tagging process to overcome signals which oxidize at similar 
potentials (Chapter 3), a novel material, and architecture were created to allow 
sequential detection within a complex mixture of multiple biomarkers (Chapter 4 
and 5).
The methodology for the uric acid detection alongside other biomarkers 
was evaluated using real physiological samples to ensure the clinical viability of 
the final prototype (Chapter 4 and 5). These experiments were verified versus the 
standard UV-Vis protocol used to validate clinical investigation data at the Royal 
Surrey Hospital. Lastly, the novel electrode was combined with the technique
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which was developed to cater for sequential testing and proven to separate out 
ascorbic acid, uric acid and glucose in a combined mixture both directly using 
peroxide detection and in the presence of a mediator. Thus the final product 
demonstrates the feasibility of multianalyte testing for near patient monitoring of a 
variety of different clinical conditions.
Aim & Objectives
Aim
• Develop novel decentralised testing of uric acid 
Objectives
• Review the applicability of uric acid as a biomarker
• Investigate the electrochemical properties of uric acid and its interactions 
with other electro species present in physiological fluids
• Develop novel materials and electrodes for a disposable uric acid sensor
• Check the clinical viability of any biosensing techniques developed for uric 
acid detection
• Assess the transfer ability of any prototypes for multianalyte sensing
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Chapter 1: Introduction 1
1 Introduction
Uric acid (UA) has long been acknowledged as a key interferent in the 
application of electrochemical techniques to the analysis of physiological fluids 
[1,2]. Its ubiquity within the latter and the fact that it can often be oxidised at 
potentials lower than those required to oxidise most other physiological analytes 
(or pharmacological agents) are the chief problems. The unwanted contribution 
from relatively high concentrations of urate can lead to, at best, ambiguous 
signals and, at worst, an amplification of the signal leading to gross over­
estimation of the intended target’s concentration. It is of little surprise therefore 
that technological and procedural strategies aimed at minimising the effects of 
urate on the electroanalytical signal have proliferated over recent years. The 
analytical value of detecting urate, however, has often been overlooked but more 
recent clinical investigations have revealed that the purine is a key player in a 
number of metabolic processes that are of considerable diagnostic significance 
[3]. Research into hyperuricemia is common because it is often a symptom of a 
more serious condition such as diabetes [4-7], it is diagnosed from excess levels 
of UA in the blood and urine (hyperuricuria). Persistent abnormal levels 
eventually lead to the deposition of sodium urate crystals in the joints of the 
extremities and in renal interstitial tissue resulting in gout. While commonly 
regarded as an indicator of gout [8], current interest in metabolic syndrome has 
identified urate as a versatile handle through which the progress of 
cardiovascular [3, 8-14], kidney diseases [15-19] and a number of other diabetic 
complications can be gauged [20-26].
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It could be anticipated that the analysis of urate, in combination with a variety of 
other key biomarkers, could allow a more rounded evaluation of physiological 
wellbeing. A key example would be the combined analysis of glucose and urate 
where the latter could provide an indication of the early onset of potential 
cardiovascular complications common to diabetics [20-22]. The practical 
exploitation of such will however be dependent upon the development of 
technologies that can allow the concentrations of such species to be speedily 
evaluated. It could be hoped that this is achievable within the immediate clinical 
setting by the attendant biomedical staff but, at present, most investigations 
require referral of the blood sample to a central laboratory for analysis. There is a 
clear opportunity for near patient testing (NPT) through electrochemical means, 
with the portability and relatively inexpensive nature of the electronics providing 
strong foundations for the development of more sophisticated devices. The key 
question that needs to be addressed, however, is whether the technologies exist 
to promote sequential multi-analyte screening within a sensing platform that is 
inherently disposable but also cost effective.
The aim of the research presented herein has sought to explore the 
technological advances that have been made in recent years towards the 
selective analysis, removal or repulsion of urate from sensing substrates and 
critically evaluate how they could, in fact, be exploited as a basis for a multi 
analyte sensor incorporating urate detection. Numerous strategies have evolved 
in recent years but these have invariably focused on the manufacture and 
response characterisation of discrete sensors. The route through which the 
technology can be transferred to a clinically relevant format that is economically
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viable is often unclear. One aim has been to collate and highlight the diversity of 
technological approaches in which urate is the central player, but with a view to 
critically uncovering the synergies that exist between seemingly contrasting 
approaches and which could be harnessed in the continued evolution of 
decentralised screening devices.
1.1 Clinical Significance of Urate
A detailed description of purine biochemistry is beyond the scope of this 
thesis but a presentation of the salient aspects of the clinical arenas in which 
urate participates is however required. UA arises within physiological fluids as a 
result of various biochemical processes involving the production / consumption of 
nucleic acids. An abridged reaction scheme detailing some of the more pertinent 
transitions, and particularly those of significance within electroanalytical contexts, 
are highlighted in Figure 1-1. While the typical concentrations of UA within serum 
normally reside in the 100-400 pM range [27], substantially increased UA levels 
(550 pM and above) have been recognised as being symptomatic of a number of 
diseases. The more prominent of these include cardiovascular [8-10, 12-14, 20- 
22] and renal diseases [15-19], arthritis [28, 29], stroke [22, 30-34], and pre­
eclamptic conditions [35-38]. Numerous studies have examined the capacity for 
urate to serve as a scalable and independent risk factor in the assessment of 
cardiovascular disease. There is now a substantial body of epidemiological data 
to support such an association [8-14] particularly for those patients identified as 
suffering from hypertension, heart disease or diabetes [20-26]. It has been 
estimated that patients with both hypertension and hyperuricemia have a 3 to 5
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fold increased risk of coronary artery disease (or cerebrovascular disease in 
diabetics) compared with normal control subjects [10].
A
Adenine Guanine
NH NH
Hypoxanthine Xanthine
H20
B Electrochemical Detection 
Options
co7
Allantoin
(IV)
Uric Acid
+2e, +2H
h 2o
(II)(III)
Figure 1-1: A) Abridged pathways detailing the enzymatic conversion of key purine bases 
to urate and allantoin. B) Electrochemical conversion of urate.
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While the pathogenetic role of urate in cardiovascular disease remains the 
subject of debate, elevated levels are widely acknowledged as being deleterious 
to a number of physiological functions that include endothelial dysfunction, 
oxidative metabolism, platelet adhesion, hemorheology and aggregation [10]. 
Pharmacological intervention to reduce urate levels (inhibition of xanthine 
oxidase or uricosuric agents) has been widely adopted and while these can be 
effective, their ability to subsequently / reversibly alter cardiovascular outcomes 
is, at present, unclear. What is apparent is that serum urate can be used as a 
robust tool in the overall risk assessment of cardiovascular disease.
Centuries ago gout was described as "the disease of kings, the king of 
diseases" and was associated with high living and superior social status. 
However, it has now been established that while the diet does affect gout it is not 
the cause but instead it occurs from certain biochemical processes breaking 
down. The disease is also a hereditary condition [8]. Gout is classed as a type of 
arthritis and characterised by increased UA levels with the result of sodium urate 
deposits in the extremities particularly the big toe. Research has shown that gout 
is associated with ischemic heart disease and hyperuricemia, which in turn are 
associated with diabetes and hypertension. Currently it is not known whether 
monitoring UA levels in gout would help to predict a gout attack but it is certain 
that a patient and their carers can make better choices about diet if they can see 
the bigger picture of their UA pattern changes, in a similar manner to a diabetic 
monitoring their glucose levels.
The use of urate measurements in prenatal care has also risen to 
considerable prominence in recent years as the correlation between elevated
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concentrations with maternal and foetal morbidity has become clearer. 
Hyperuricemia has long been associated with pre-eclampsia, which is a disorder 
that occurs only during pregnancy and the postpartum period and affects both the 
mother and the unborn baby. It is estimated to occur in at least 5-8% of all 
pregnancies (although rises to nearly 18% in developing countries [39]) and while 
it can be characterised by a diverse range of physiological symptoms, many of 
these are subjective and often disregarded by the mother as a natural 
consequence of the pregnancy period. It is equally possible that in rapidly 
advancing conditions, few physical symptoms will arise before the need for 
clinical intervention. This and other associated hypertensive disorders of 
pregnancy are leading causes of maternal and infant illness and death (estimated 
at over 76,000 cases per year internationally [40]). Increased serum urate is 
thought to arise through a marked reduction in the urinary excretion of the purine 
as a consequence of pre-eclampsia. The role of urate in such instances may 
therefore lie more as an indicator for the condition rather than as a semi- 
quantitative biomarker for assessing its pathogenesis. The ability to routinely 
monitor serum urate would undoubtedly improve prenatal care allowing the 
possibility of early diagnosis and aid the management of the condition [37].
While urate is associated with conditions that appear to be almost 
invariably detrimental, it does however, possess more positive, anti-oxidant 
attributes that have been shown to efficiently scavenge free radicals [34, 41-45]. 
It has a distinct role in moderating the effects of oxidative stress processes that 
would otherwise promote damage to DNA, protein or lipid components. There is 
therefore some debate as to the relative protective aspects of high urate
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concentration [30, 32-34, 46]. However it has been found that these protective 
effects are predominantly exercised within hydrophilic regions of cellular and 
vascular structures and at the lipid aqueous interfaces, with little or no protection 
found within lipophilic environments [41].
The versatility of urate as a biomarker is clear and while any diagnostic 
result will still require medical expertise in terms of interpretation, there is a strong 
requirement for its measurement directly within near patient contexts. Routine 
screening and the ability to provide immediate responses to the clinician at the 
time of consultation would obviously be highly beneficial in the identification and 
subsequent treatment of those at risk of cardiovascular disease, pre-eclampsia or 
gout etc. Another key question is whether the technology exists to provide a 
device that will be sufficiently robust for use by non-expert staff under non­
laboratory conditions?
1.2 Electrochemistry of Urate
A cyclic voltammogram detailing the electrochemical behaviour of urate 
(1 mM, pH 7) at a conventional glassy carbon electrode at a scan rate of 
200 mVs"1 is shown in Figure 1-2. The profile is characterised by a 2e' oxidation 
process observed at +0.36V and has been widely studied using a variety of 
spectroelectrochemical and hybrid techniques. The mechanistic and kinetic 
intricacies of various substitutions upon the purine base have been extensively 
explored and reviewed [47, 48] but, in summary, the oxidative pathway for urate 
has been found to lead to allantoin through a 2e", 2H+ process [48]. The basic
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scheme is outlined within Figure 1-1 in which urate (I) is first converted to the 
reactive di-imine species (II).
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Figure 1-2: Cyclic voltammogram of 1mM UA in Britton Robinson buffer at a glassy carbon 
electrode vs Ag/AgCI at pH 7, sweep rate 200 mVs'1.
Increasing scan rate (> 1 Vs'1) leads to the re-reduction of the dimine before 
nucleophilic attack from water and the production of the imine alcohol (III). After 
the addition of a second water molecule, there is the final intra-molecular 
degradation to allantoin (IV). The electrochemical oxidation effectively mirrors the 
process performed by the uricase enzyme alluded to in Figure 1-1. A key point to 
note is the low potential required to induce the oxidation of urate under 
physiological conditions and serves to emphasize its capacity for interfering in the 
measurement of other key biomarkers. The response to urate can be significantly 
improved through the use of pulse waveforms -  particularly squarewave -  with 
the peaked profiles often aiding resolution between the different components 
within the sample. Square wave voltammograms detailing the response of a
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glassy carbon electrode to the key purine biomarkers through which urate can
arise are detailed in Figure 1-3, these 
include xanthine (XA), hypoxanthine 
(HX), guanine (Gu) and adenine (Ad).
Where the direct oxidation of the 
other moieties would incur interference 
from other physiological components, it 
could be anticipated that the low 
oxidation potential exhibited by urate
could therefore serve as a more
accessible means through which the
others could be quantified. The key to 
achieving such has already been
highlighted in Figure 1-1A where the 
addition of suitable enzymes to the 
electrode assembly could, in principle, 
facilitate a cascade to the endpoint urate. 
The urate concentration is then
proportional to the concentration of the original target purine (providing the 
endogenous urate is subtracted).
The versatility of such an approach has been exemplified through the
detection of phosphate [49, 50). The inaccessibility of the latter to direct
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Figure 1-3: Square-wave 
voltammograms of various purine 
derivatives (UA=XA=Gu=Ad 50 pM, 
HX= 200 pM) recorded at a glassy 
carbon electrode in pH 7 buffer.
electrochemical detection has long been a problem but can be overcome through
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harnessing the enzymic transformation of inosine (Figure 1-4) in which 
phosphate is a crucial ingredient.
HOCH.
NP
x pC °
> OH
OH OHOH OH
Inosine 
o
"A
O N I
H
Ribose-1-phosphate
+  9
XOD
Hypoxanthine
Figure 1-4: Reaction pathway detailing the conversion of inosine to urate through the 
combined use of nucleoside phosphorylase (NP) and xanthine oxidase (XOD).
The release of hypoxanthine could have been used as the electro- 
oxidisable label but, as demonstrated in Figure 1-3, requires the imposition of a 
detection overpotential that would court interference. The introduction of xanthine 
oxidase adds to the complexity and expense of the system but, significantly, this 
is deemed to be a worthwhile trade off for the acquisition of the low detection 
potential and sensitive current responses offered by the urate endproduct [49-51].
1.3 Strategies for Improving the Detection of Urate
While the detection of urate within simple systems can be accomplished 
with relative ease on a variety of bare electrode substrates, the transfer to real 
samples inevitably brings complications otherwise absent in a clean buffer. In
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contrast to most other analytes, the determination of urate is however generally 
free from the interference of other electroactive components -  bar one. Ascorbic 
acid (AA) poses a considerable problem given that it is one of the few 
components present within biofluids that can be oxidised at potentials similar to, 
or lower than, that of urate.
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Figure 1-5: Square-wave voltammogram detailing the response to equimolar (300 pM) 
ascorbate (AA) and urate (UA) at a carbon fibre electrode (1 cm diam). Inset: 
Response at the carbon fibre electrode after electrolytic pre-treatment (+2V, 
0.1 M NaOH, 15 min) [52].
This is highlighted in Figure 1-5 where a squarewave voltammogram 
recorded using a carbon fibre electrode [52] details the response to equimolar 
ascorbate and urate (300 pM, pH 7). Several catecholamines are also oxidised at
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low potentials and are capable of overlap with the urate electrode process but are 
normally present at low concentrations (i.e. dopamine < 5 nM, epinephrine 
<5 nM, norepinephrine <5 pM) that would impart little to the overriding purine 
signal [53]. This contrasts the reverse case where massive interference is likely 
and is why a great deal of effort is expended in minimising urate (and ascorbate) 
electrochemistry and these are discussed in later sections.
Ascorbate is commonly present within 23 to 85 pM (clinical reference 
ranges in serum) but will obviously depend on dietary/nutritional factors as well 
as the physiological wellbeing of the individual from whom the sample was 
extracted [53]. Nevertheless, it is probably no surprise to find that most of the 
procedures that focus on the quantitative evaluation of urate concentration 
incorporate strategies aimed at minimising the influence of ascorbate in 
deference to most other components. While there is a degree of separation 
between the two electrode processes shown in Figure 1-5, ascribing a baseline 
from which to quantify urate in the presence of variable ascorbate will clearly be 
problematic.
The various approaches taken to aid the quantification of urate [54-83] are 
briefly summarised in Tables 1-1 and 1-2 and correspond to direct [54-73] and 
enzymatic [74-82] detection methodologies respectively. Voltammetric techniques 
predominate in the former with the current-potential profiles offering an 
opportunity for the sequential analysis of different species present within the 
sample - providing peak resolution can be maintained. Many of the techniques 
outlined employ various surface modifications either in the form of electrolytic
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surface pre-treatments [65-67], polymer coatings [68-73, 76, 77, 82] and organic 
[55, 57-59, 63, 78, 81, 82] or inorganic [56, 64, 74, 79, 80] films.
Electrode Modifier Type Sample Matrix/Analytes
LOD/
pM
Ref
B-Cyclodextrin-CNT S Urine UA 0.2 [54]
Mercaptobenzimidazole S Serum UA, AA 1 [55]
Nontronite-SPE S Plasma, Urine UA, XA, HX 0.4 [56]
Glutamic Acid S Urine UA, AA 1.1 [57]
Cysteine S UA 0.4 [58]
8-Mercaptoquinoline S NADH, UA, AA NS [59]
CNT S Urine UA, AA 0.1 [60]
CNT . S Serum UA, AA NS [61]
CNT-CPE S UA AA, H202 NS [62]
Mercaptobenzimidazole S Serum UA, AA 0.1 [63]
Methylene Blue
SoIG Urine UA, AA 1 nM [64]
Anodised C-F PrT UA NS [65]
Anodised BDD PrT Serum & Urine UA, AA 0.01 [66]
C-Powder PrT Serum & Urine UA NS [67]
Nation PF Urine UA 0.3 [68]
Nation PF Urine UA 0.01 [69]
Poly(4-Aminopyridine) PF Urine UA 1 nM [70]
Poly(N.N-dimethylaniline) PF UA, AA 1.2 [71]
Po!y(4-vinylpyridine)Polymer PF Urine UA 0.1 [72]
Carbon-polyvinylchloride CF Serum & Urine UA, DP, AA 0.1 [73]
Gold Microelectrode-Palladium S Urine UA, AA NS [83]
Anodised-GCE PrT Urine UA 9 nM [84]
Anodised GCE, Au & Pt PrT AA UA 0.1 [85]
Anodised Nation PrT, PF Urine UA 10 nM [86]
Screen Printed electrode D Whole Blood UA NS [87]
Metal-Bathophenanthroline, 
poly(vinyl chloride)
CF Serum & Urine UA NS [88]
LOD- Limit of Detection, S-Surface Modification, D -  Direct Oxidation, SoIG -  Solgei, PrT -  Electrolytic Pre-Treatment,
PF-polymer Film, CF -  Composite Film Electrode, UA - Urate, AA -  Ascorbate, XA -  Xanthine, HX - Hypoxanthine,
DP-Dopamine, NS -  Nonspecified
Table 1-1: Details of electrode modifiers
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Electrode Modifier
Detection
Mode
Sample Matrix
LOD / 
pM
Ref
Fe Salen Complex Peroxide Red. UA 0.1 [74]
n-Ontanethiolate and L-alpha-
Phosphatidylcholine beta- Peroxide Ox. Blood UA NS [75]
Oleoyl-gamma-palmitoyl
Nation Peroxide Ox. UA, Glu, Lacl.O 2.5 [76]
Poly(allylamine)/poly(vinyl
sulphate)
Peroxide Ox. Serum UA, AA, PA 1.0 [77]
Poly-O-Aminophenol-Aniline Peroxide Ox. UA NS [89]
Dodecylsulphate Doped 
Poly(N-Methylpyrrole)
Peroxide Ox. UA
NS
[90]
Silk fibroin Oxygen Red. Serum UA NS [78]
Teflon -  UOx/HRP Oxygen Red. UA 0.1 [79]
2-Aminoethanethiolate /  
[Fe(CN)6](3-)
Mediated Blood UA NS [80]
Dithiothreitol Serum Mediated Urine 0.3 nM [81]
5-Methylphenazinium poly(N-
Methyl-o-phenylenediamine),1- Mediated UA NS [82]
Methoxy-5-methylphenazinium
LOD- Limit of Detection, Red.-Rduced, Ox.-Oxiized, UOx -  Uricase, HRP -  Horseradish Peroxidase, UA -  Urate, 
Glu-Glucose, Lac -  Lactate, AA -  Ascorbate, PA -  Paracetamol, NS -  Nonspecified
Table 1-2: Details of Electrodes with enzyme modifiers
In most cases, the aim of the modification is either to decrease the 
operating potential required to oxidise urate and increase the separation between 
it and ascorbate. The addition of modifiers to the electrode surface have been 
extensively investigated and, as indicated in Table 1-1, a variety of different types 
of material have been found to influence the over-potential and peak separation 
for UA and AA [55, 57, 60, 71, 72]. These investigations give rise to many 
fundamental insights into the interfacial electron transfer processes such as the 
edge plane defects in carbon nanotubes [54, 60-62, 91]. Typical reductions in
Chapter 1: Introduction 15
over-potential lie within the 200-300 mV range but similar results can often be 
achieved through electrochemically pre-treating the base substrate prior to the 
analysis.
Electrolytic treatments are generally employed with carbon-based 
substrates (whether glassy carbon, carbon fibre, graphite, boron doped diamond) 
[65-67]. Carbon substrates, irrespective of form, present a heterogeneous 
interface that bears carboxyl, phenolic and quinoid components -  whose 
respective populations can be modified through the extremes of potential applied 
during the pre-treatment process [65-67].
Metallic electrodes (Au, Pt, etc) can also possess a degree of 
heterogeneity through variations in oxide coating but while susceptible to 
electrolytic modification (exemplified by the use of multi-step waveforms in pulsed 
amperometric detection [2]), generally have less influence on the over-potential of 
urate. In those circumstances where metallic electrodes are utilised, electrode 
modifiers will often be the principal means through which a selective response to 
urate can be obtained. Key examples are the interactions of thiol-based derivates 
with gold substrates where the chemistries of the resulting monolayer can impart 
a higher degree of selectivity [55, 59, 63, 80, 82].
The pursuit of modifiers possessing the ability to lower the operating 
potential has much more significance for those involved in commercial sensor 
development, particularly those wishing to exploit screen printed substrates as a 
disposable sensing platform. The electrolytic pre-treatment can provide a “green” 
chemistry option in terms of minimising the use of chemical additives, but, the 
ability to simply mix the modifier (i.e. nontronolite [56] or nanotube [54, 60-62])
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within the base ink or carbon paste and thereby directly improve the electrode 
characteristics provides a procedurally simpler one-step option.
Amperometric detection is favoured by most commercial devices, often on the 
basis that the instrumentation required to effect the oxidation (at a single fixed 
potential) of a particular analyte, at least in principle, is substantially simpler than 
the sweep / pulse requirements in voltammetric analysis. The main problem in 
this instance relates to the fact that ascorbate, being easier to oxidise, will 
contribute to the current and hence lead to an over estimation of the urate 
concentration. The use of uricase enzymes (Figure 1-6) is one solution to the 
problem whereby the hydrogen peroxide by-product serves as an indirect 
indicator for the purine. The measurement of the peroxide is accomplished 
through either oxidation (Figure 1-6, A) or reduction (Figure 1-6, B). In either 
case, a large over-potential (whether anodic or cathodic) has often been required 
to drive the process and achieve a measurable current. The obvious problem 
being that the imposition of a large potential can stimulate unwanted electrode 
processes that will contribute to the analytical signal. This route is therefore often 
employed in conjunction with some form of surface modification to improve the 
selectivity towards peroxide -  which typically means precluding access of most 
other species to the underlying electrode substrate.
Recent investigations however have led to the introduction of various 
surface modifiers capable of catalysing peroxide conversions such that the 
operating potential of the sensor can be minimised. Some of those specifically 
utilised with uricase are highlighted in Table 1-2.
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Figure 1-6: Schematic representation of the various detection strategies that can be 
employed when using Uricase (UOx) enzyme systems.
The use of cathodic operating potentials for the reduction of peroxide 
offers the advantage of completely avoiding the direct oxidation of ascorbate. The 
metallo-salen complex has been shown to facilitate the reduction of peroxide 
(-0.4V) arising from uricase [74]. However, the options presented in Table 1-2
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reflect only a minor portion of the work that has been done to enhance peroxide 
catalysis within enzyme electrodes. Many alternatives have actually arisen 
through studies aimed at alleviating the interference effects of urate rather than 
facilitating its detection. Given that they act solely upon peroxide, they are 
essentially independent of the sensing enzyme and will therefore be equally 
applicable to the uricase arrangement. Common examples are Prussian Blue 
[89, 92-96] and other mixed metal hexacyanoferrates [97], and electrodeposited 
metals and alloys (typically Ir / Cu / Pd / Ru) [98-100] and carbon nanotubes 
[54, 60-62].
Oxygen is also an important player in the enzymatic reaction and is 
regarded as the natural mediator responsible for regenerating the active site 
(Figure 1-6, C). Thus, its localised consumption at the electrode interface can 
also be used as a means of estimating urate. The advantages inherent to 
measuring oxygen reduction are analogous to the case of peroxide reduction in 
that the cathodic potentials neatly avoid the oxidation of ascorbate. This 
approach can therefore be used without any form of electrode modifier other than 
that used as immobilisation matrix for the enzyme and contrast the exclusion 
approach employed in the oxidation methodologies highlighted in Table 1-2. The 
oxygen reduction process is however subject to two major drawbacks -  the first 
being the poor response time and the second being that the electrode system is 
dependent upon the concentration of oxygen within the original sample. The 
oxygen-peroxide process can however be completely circumvented through the 
use of an artificial mediating system in which a reversible redox mediator 
effectively shuttles electrons between active site and electrode substrate. This
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process is highlighted in Figure 1-6, D. Ferrocyanide 
and a range of substituted phenazine derivatives 
(Figure 1-7, A) have been shown to be capable of re- 
oxidising the uricase enzyme with regeneration of the 
mediator at the electrode providing the analytical signal 
[80-82].
The need for a mediator would appear to 
increase the complexity of the system but it must be 
noted that commercial glucose sensors invariably 
employ diffusible mediators based on ferrocyanide or 
ferrocene derivatives and these are simply added to 
the enzyme paste prior to printing the sensing strip. An 
increasingly common alternative involves the 
“molecular wiring” of the enzyme to the electrode 
through the use of redox polymers. This strategy has 
been widely investigated with a whole range of 
enzymes and polymers but their operation is not within 
the scope of this research. The uricase example 
considered here however pursues a slightly more 
sophisticated route in which the electropolymerisation 
of N-methyl-1,2-diaminobenzene not only serves to 
entrap the enzyme but also provides a redox chain 
through which electrons can be exchanged with the
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underlying sensor substrate [82], The basic reaction scheme is shown in 
Figure 1-7, B. The novelty in this work lies in the in-situ formation of substituted 
phenazine groups within the polymer that effectively mimic the solution-based 
mediator. The prime advantages of the approach being that the enzyme and 
mediator are confined to the electrode with the resulting sensor independent of 
oxygen concentration.
A third approach in the quantitative detection of urate involves capillary 
electrophoresis (CE) in which the components of the biofluid are sequentially 
analysed [101-106]. These are summarised in Table 1-3.
Analytes Sample Matrix Electrode Type
LOD
pM
/
Ref
CSH, GSH, AA, UA Blood CF-Au-Hg 2.4 [101]
UA, XA, HX, Ad, Gu, Thp Urine C 0.1 [102]
UA, DP Urine Pt 1.0 [103]
PA, UA, Glu, AA Buffer Au 5.0 [104]
Gu, HX, XA, UA Buffer BDD NS [105]
Glu (H202), UA, AA Buffer Au NS [106]
LOD- Limit of Detection, CSH - Cysteine, GSH -- Glutathione, AA -  Ascorbate, UA - Urate, XA - Xanthine, HX -
Hypoxanthine, Ad - Adenine, Gu - Guanine, Thp -  Theophyline, DP -  Dopamine, Glu -  Glucose, PA -  Paracetamol, CF -  
Carbon Fibre, BDD -  Boron Doped Diamond, NS -  Nonspecified
Table 1-3: Details of various materials used for electrodes
While these can effect a highly sensitive evaluation of a range of potential 
biomarkers, the practical utility of CE technologies for use by non-expert staff 
within NPT contexts [107-110] is however questionable and it is likely that these 
techniques will remain, at least in the near term, laboratory based. The 
advantage inherent to most of the direct electrochemical probe systems outlined
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in the previous discussion is that they are capable of harnessing the simple pin 
prick blood sampling technology analogous to that utilised by existing glucose 
and cholesterol meters. The final question that remains to be addressed is 
whether the wealth of information that has built up in recent years relating to 
individual sensing applications can be combined such that multiple analytes can 
be analysed within a single strip without incurring problems of signal crosstalk. An 
alternative solution has been to exhaustively oxidise each component at each 
given step such that the following potential step starts from a near zero baseline 
[67]. This has consequences in terms of the time required to complete the total 
conversion of each component before moving onto the next. The efficacy of this 
approach was however demonstrated through the use of a carbon powder 
electrode system in which the large surface area combined with small sample 
volume facilitates complete removal of ascorbate followed by urate [67]. The new 
generation of carbon nanotubes have been shown to significantly modify the 
over-potentials of ascorbate, urate and peroxide [62] and it could be envisaged 
that these could be easily incorporated as the substrate of choice within the next 
generation of screen printed sensor.
The evolution of single analyte sensors to dual or triple analyte 
measurements can clearly be achieved at a single substrate. There is however 
little scope for further progression and is essentially limited to a single enzyme 
system. The pursuit of sensors employing multiple enzymes will require the use 
of a multitude of sensing electrodes but this can be accommodated within the 
screen print practices currently employed for commercial electrode manufacture 
-  requiring only the integration of additional print layers. The simple single shot,
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single analyte strip that currently embodies glucose testing involves the re­
solubilisation of the enzyme (and associated electrolyte, mediators, etc) upon 
delivery of the blood sample. This would obviously be impractical within a multi 
oxidase system where the peroxide byproduct from each enzyme would be free 
to diffuse to different sensing electrodes causing crosstalk interference. Confining 
the enzyme directly at the appropriate electrode surface would have the effect of 
essentially localising the generation of peroxide. The main requirement is that the 
analysis time is short such that diffusion of the peroxide from one site to another 
is minimised. The permselective barriers that have been frequently used to 
exclude urate now come into play whereby their macromolecular scaffold can 
essentially trap the enzyme at the respective electrode surface, Figure 1-8.
Sequential 
Addressing of 
Individual 
Sensors
Localised
Permselective
Membranes
Analyte 1 
Enzymic 
Product 1
Target Analyte 2 
('“) Enzymic 
Product 2
Urate
, j  Allantoin
Figure 1-8: Schematic representation of multi-anaiyte screening devices incorporating 
multiple enzyme sensors.
Chapter 1: Introduction 23
Providing the screen print process can facilitate the requisite spatial control 
for the isolated deposition of each enzyme and subsequent polymer layers then it 
should be feasible for a multi-sensing system to evolve. Modern offset printing 
(whether screen or pad) can offer print resolution of the order of a micron, with 
further refinements possible and indeed likely upon the introduction of ink jet 
spotting [111-114]. The last addition is the inclusion of a combined sensing pad 
for ascorbate and urate -  which could be printed with an appropriate modifier 
from Table 1-1.
1.4 Conclusions
The importance of urate measurements have been outlined but it is clear 
that the concentration of a single type of biomarker can be influenced by a 
number of factors and that the subsequent ambiguity may actually lessen the 
diagnostic value of the initial test. There is a strong need within clinical settings 
for the provision of devices that can facilitate the determination of a range of 
biomarkers -  much as what would be returned from a centralised biochemistry 
laboratory acting on a conventional blood test. The additional information 
essentially allows the clinician to identify the underlying condition at hand and 
allow a more targeted assessment of the disease progression or treatment. A 
prime example being some forms of pre-eclampsia where there may be little 
physical symptoms to guide an initial / early consultation but where the results of 
a urate test may reveal cause for concern. The ability to provide an immediate
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blood screen response within a general practitioner’s surgery would be the 
preferred option.
The technologies outlined in this review are clearly well positioned to 
provide the foundations of such a device. The procedures required for both the 
determination of urate and its exclusion from neighbouring sensors are mature. 
The information presented within Tables 1-1 and 1-2 highlight the fact that the 
sensors are already more than capable of acting upon a range of biofluids 
whether serum, plasma or urine with detection limits that are supremely adequate 
for routine screening. The challenge now rests upon the integration of both 
aspects of urate electrochemistry such that a single sensing strip can emerge 
which is capable of providing multi-analyte testing.
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2. Experimental Methodology
There is a promising future set for electrochemical sensors (EC) over a variety 
of applications particularly within the clinical diagnostics sector. One 
commercial opportunity, which this project strives to take advantage of, is near 
patient monitoring (NPT) technology. The key objective with the experiments 
was separating and detecting a variety of electroactive species in a single 
solution. The separation was achieved through manipulation of the applied 
potential and modification of the electrode surface. The resulting techniques 
achieved high sensitivity and low detection limits, which are required for 
clinical tests.
2.1. Cell Setup
Electroanalytical measurements concentrate on reactions, which occur 
at the electrode-solution interface of the working electrode (WE). When an 
electrode is submerged into a solution, a phase boundary is produced 
between molecules adjacent to the electrode and the rest of the solution. Any 
electroactive material further away can be considered at an infinite distance 
from the electrode due to its lack of interaction with the surface. It is important 
to account for any chemical and physical influences on this boundary area 
when running an electrochemical experiment. These interactions include 
charge transfer and mass transport, which will be discussed in more detail 
later. Although the principal reaction occurs at the WE, the cell geometry must 
still be considered as an important part of the overall system. The physical 
structure of the cell can take many forms, for optimal results the nature of
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each experiment must be taken into consideration. The physical and chemical 
character of the analyte under investigation ultimately determines the material 
of the cell, electrodes and background electrolyte.
The standard laboratory system used throughout the investigation 
consists of a three electrode system: the WE, reference (RE) and counter 
(CE) electrode, the CE may also be referred to as the auxiliary electrode in 
some referenced papers. A three electrode system will be assumed with a 
standard laboratory setup (Figure 2-1).
Thermostated 
glass c e l l ^
CEWE
.Porous
Frit
Water^
outlet"
Potentiostat
Figure 2-1: A three electrode electrochemical cell with control instrumentation.
2.2. Electrodes
As seen in Figure 2-1 there are three main electrodes required for 
these research experiments, each plays a vital role which will be explained in 
turn.
2.2.1. Reference Electrode
The primary requirement of the RE is to provide a constant, drift free 
potential that is unaffected by the composition of the sample solution. The 
standard hydrogen electrode is often employed to measure electrode 
potentials. While this is an accurate reference, it is not very practical for every
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day laboratory conditions. An alternative RE employs a silver wire coated with 
AgCI, isolated within a glass sleeve in 3M KCI solution with a porous frit that 
allows a slow outflow of the reference electrolyte into the sample solution, to 
allow electrical contact. The redox process for this electrode is:
AgCI(s) + e' <-> Ag(8) + Cr(aq)
The potential E for any electrode is determined by the Nernst equation, which 
relates E to the standard potential E° and the activities a of the redox 
components. The Nernst equation for the Ag/AgCI electrode is:
E = i r r )
The AgCI and Ag terms cancel out because their activity is 1. If the activity of 
the chloride ion is maintained at a constant level then E will remain constant 
therefore this couple can be used as a reference. It is generally more 
convenient to consider concentrations rather than activities. These parameters 
are related by the activity coefficient y:
aCI'= y Cl'.[ Cl]
Activity coefficients use the Debye-Huckel theory, which considers ion size 
and electrostatic force effects on concentration, giving the ionic strength of a 
solution. It is important to take activity into consideration because an electrode 
will effectively “perceive” fewer ions than there are due to various electrostatic 
positioning of the ions in solution. However, by flooding a sample with a 
background solution of constant ionic strength for each sample, the difference 
between activity and concentration is negligible. Unless otherwise stated this 
was done for all experiments by using a pH adjusted buffer.
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2.2.2. Counter Electrode
The counter electrode is required to complete the WE circuit and avoid 
current passing through the RE. Essential features for the CE are a 
conductive, chemically inert material, preferably with a large surface area. The 
research experiments used a platinum wire unless otherwise stated.
2.2.3. Working Electrode
The WE is where the reaction of interest takes place. Electrode 
materials that are good electron conductors and cover the required potential 
range (Figure 2-2) are needed. Two electrode materials were used for the 
initial research: the first was the glassy carbon electrode (GCE). Glassy 
carbon or vitreous carbon is a form of pure carbon produced by the thermal 
decomposition of a three-dimensionally crosslinked polymer giving it excellent 
resistance to a wide range of aggressive chemical environments, thus, it can 
be used as an alternative material to precious metals.
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Figure 2-2: Approximate potential ranges for platinum, mercury and carbon in aqueous 
electrolytes.
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In technical terms, true amorphous carbon has localized u  electrons 
(as opposed to the aromatic i t  bonds in graphite), and its bonds form with 
lengths and distances that are different to most other allotropes of carbon. The 
electrode is polished to a glassy finish with micron alumina powder between 
experiments to reveal a fresh layer of material; the electrode is then sonicated 
for a minute to remove any adsorbed alumina particles. The second material 
used was the screen-printed electrodes, which were supplied by Inverness 
Medical Lifescan. The screen-printing process has been established for well 
over a decade for glucose testing with a standard stepwise fabrication 
(Figure 2-3).
Top Film
'  Vs-------------------V Hydrophilic Tape
— —  --------  Adhesive Layer
Enzyme Layer
Insulation Layer.
\ Substrate
Figure 2-3: Schematic breakdown of screen-printed glucose strip
However, the strips used for UA research had only the WE carbon area with 
no RE or enzyme/mediator layer. The operating window for the WE is 
determined by the solvent decomposition i.e. the oxidation or reduction of the 
solvent. This usually means the reduction of protons to yield hydrogen or the 
oxidation of water to yield oxygen:
2H+(aq) + 2e‘ —» H2(g) Cathodic limit
2H20(i) —► 0 2(g) + 4H+(aq) + 4e' Anodic Limit
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Other aspects of the working limits include decomposition of the supporting 
electrolyte, electrode dissolution or formation of a layer of insulating/semi­
conducting substance on its surface (oxide). Using a non-aqueous solvent, 
e.g. acetonitrile, can often extend the potential range of the working system.
Generally, the background solutions are a combination of solvent and 
supporting electrolyte. The solution needs to allow passage of current over a 
wide potential range, and if possible, not contribute to chemical or 
electrochemical reactions. Britton Robinson (BR) buffer was used for the early 
experiments and consists of three different acids: acetic, phosphoric and boric 
acids. It was adjusted using sodium hydroxide to the required pH, phosphate 
buffer was used for the glucose experiments in the later research to avoid the 
possibility of glucose complexing with borate from the BR buffer.
2.4. Mass Transport
There are three key physical processes, which must be taken into 
account when carrying out electrochemical experiments: diffusion, migration 
and convection.
2.3. Buffer Solution
A — ► O + e
lectrode Surface
°  9 
9 9
O  Reactant A  
0  P roductO
Figure 2-4: Schematic of mass transport processes at the electrode surface.
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These are taken into consideration because the analysis is limited by the 
transport of the analyte to the electrode and transport of any reacted species 
away from the electrode surface (Figure 2-4).
2.4.1. Diffusion
In many respects, the simplest and best understood process 
influencing electrochemistry is diffusion. Fick first described diffusion by 
considering the simple linear case to a planar surface. Fick was able to show 
the relationship between [C], concentration of the species under investigation 
and D the diffusion coefficient:
5[C]
J=-D 8 x
Where J ‘the diffusional flux’ is the number of moles of material diffusing 
through a unit area in one second. During electroanalytical experiments it is 
necessary to know the change in concentration at a point (such as that 
adjacent to the electrode surface) as a function of time. This can be 
established by considering the variation in concentration of material within the 
region x to x+ dx, during a time interval dt. This is simply related to the 
difference in flux of [C] entering through the plane at x  and the flux leaving 
through the plane at x+dx during time (t), as demonstrated in Figure 2-5:
Pi
Flux in d t Flux out
DC DC +  dD C
Figure 2-5: Schematic of flux, separated by a distance dt.
Fick’s second law of diffusion enables the prediction of concentration changes 
of electroactive material close to an electrode surface:
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5[C]_D(52[Cn
5 t  u \  W *  )
2.4.2. Convection
Convection is the hydrodynamic movement of the sample solution 
resulting in transport of reactants to the electrode surface whilst carrying the 
electrogenerated product away. Two distinct types of convection can be 
described, the first is natural convection, which can be present in any solution 
and arises from thermal gradients and/or density differences within the 
solution. In electrolysis reactions, a thermal gradient may arise simply as a 
result of the exo- or endo-thermicity of the process, and the density changes 
as a result of the electrode reaction creating a product near the electrode of 
different density to those of the reactants in bulk solution. Natural convection 
typically becomes significant when electrolysis is conducted with electrodes of 
approximately mm2 or larger, on the time-scale of 10-20 s and longer, and is 
generally undesirable since it is difficult to predict. The second type of 
movement is forced convection; this could include stirring the solution, rotating 
the electrode, degassing the solution or a flow of the solution through a cell. 
Forced convection is used in experiments as a means of swamping any 
contributions from natural convection, ensuring that reproducible experiments 
can be made over time-scales beyond a 10-20 s limit. In particular, the forced 
convection is usually arranged to possess well-defined hydrodynamic 
behaviour, e.g. using a rotating disc electrode. This enables a quantitative 
description of the flow in solution to be established and the pattern of mass 
transport to the electrode to be rigorously predicted. Mathematically,
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concentration changes resulting from movement of solution with a velocity vx 
can be described:
^EL-^ sjq
St * 85c
This equation is the convection analogue of Fick’s second law of diffusion.
2.4.3. Migration
Migration is the movement of a charged particle due to an electrical 
field effect. During electrochemical experiments this field effect exists in the 
vicinity of the electrodes, e.g. cations are attracted by the cathode and 
repelled by the anode. The external electric field (dQ/dx), which exists at the 
electrode/solution interface as a result of the drop in electrical potential 
between the two phases (AOWE/s) is capable of exerting an electrostatic 
force on charged species present in the interfacial region and thereby inducing 
the movement of ions to or from the electrode. These ‘migration’ effects 
contribute to the mass transport accompanying electrochemical reactions. The 
migratory flux (jm) is proportional to the concentration of the ion, [C], the 
electric field (<P) and the ionic mobility (u):
*«-urc]4 j |
The ionic mobility is dependent on the ionic charge and size, as well as on the 
solution viscosity. In most analytical techniques, the effect of migration is 
minimised by the addition of an inert electrolyte, called a supporting 
electrolyte. The electrolyte moves nearly all the charge by ionic transport from 
one electrode to the other through the solution whilst leaving the electroactive
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species unaffected by migration effects. The conductivity can be amplified by 
increasing the concentration of the electrolyte.
2.5. Voltammetry
Voltammetry is classified as a dynamic electrochemical technique in 
which the experiments are based on measuring current as a function of 
potential. The current is produced at the electrode surface following oxidation 
or reduction of the analyte at its characteristic potential. In any voltammetric 
technique the charge transfer is measured in amperes at the electrode surface 
i.e. the rate of flow of charge, thus voltammetric techniques measure the rate 
of reaction. Other processes that can be measured using this technique 
include, surface studies and quantitative information. The basis of the 
voltammetric experiments can be described using the Nernst equation:
E.E-+J L | „ f « l
nF {[Red])
So, the potential ‘E’ is manipulated to force the redox reaction to occur.
2.5.1. Cyclic Voltammetry
Cyclic voltammetry was used for most of the initial research as any 
redox processes can be seen clearly. The potential of the WE is swept from a 
value E1 where there is no electrode reaction, to a second potential E2, where 
the electron transfer is driven rapidly. When the potential reaches the value 
E2 the direction of the sweep is reversed and electrode potential is usually 
scanned back to the original value, E1. This gives a triangular potential cycle 
and the technique is termed cyclic voltammetry (Figure 2-6). Many inorganic
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compounds contain elements that may take on several different oxidation 
states.
Time (t)
Figure 2-6: Schematic of potential for cyclic voltammetry experiment.
The CV experiment provides information about the oxidation and reduction of 
an element in a compound as well as the compound’s stability in the solvent 
system. One example of an electrochemically reversible system in an 
aqueous solution is (Figure 2-7):
Fe(CN)64' Fe(CN)63' + e
The current increases initially since a high concentration of Fe(CN)64‘ is 
present at the surface of the electrode and the kinetics for the conversion of 
Fe(CN)64'to  Fe(CN)63" become more favourable as the potential increases.
Increasing
Ferrocyanide
additions
0.2 (iA
-0.1 o.o 0.1 0.2 0.3 0.4 0.60.5
Potential / V
Figure 2-7: Voltammograms of Ferrocyanide oxidation.
Chapter 2: Experimental Methodology 40
Gradually, all of the Fe(CN)64' present at the electrode surface is 
oxidised to Fe(CN)63', the current decreases, as fresh material has to diffuse 
to the electrode. As the potential is swept back there is a high concentration of 
Fe(CN)63' being reduced back to Fe(CN)64' so again the current increases in 
magnitude and a mirrored profile of the oxidation peak is observed.
The important parameters of a cyclic voltammogram (CV) are the 
magnitude of the peak currents, lPA and Ipc, and the potential at which the 
peaks occur, EPA and EPC (Figure 2-8).
8
Ep,a
6
4
Ip,a<i  2
ca>
0
-2
-4
Ep,c
■6
0.0 0.2- 0.2 0.4 0.6
Potential / V
Figure 2-8: Diagram of measurable parameters on cyclicvoltammogram scan.
These parameters are important when describing the reversibility of the redox 
system. A redox couple in which both species rapidly exchange electrons with 
the WE is termed an electrochemically reversible couple. This couple can be 
identified from a CV by measuring the previous parameters:
( - l p a ) / ( l p c )  = 1 Equation 1
Ep = Epa - Epc = 59/n Equation 2
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If both Equations 1 and 2 are true then the system can be described as 
reversible. There are two other methods of describing the electrode kinetics. 
The first is quasi-reversible where there are slow transfer kinetics for the redox 
couple and secondly, a chemical or electrochemical system where there is no 
reconversion of the product back to the reactant. The relationship for a 
reversible system can be further defined using the Randles Sevcik equation:
(
n r J /2
j^J d'/2[C K2
Where Ip is the peak current, n is the number of electrons (C/s), A is the 
electrode area (cm2), D is the diffusion coefficient (cm2 s'1) and v is the scan 
rate (Vs'1). When the square route of the scan rate is plotted against the peak 
current a straight line graph is observed for a reversible, diffusion limited 
system (Figure 2-9).
50 i
40 -
Graph no longer linear - the scan rate 
is out running the diffusion
°  20 -
10 -
200 3000 100 400 500 600 700
(Scan Rate)1/2 / (mV/s)1/2
Figure 2-9: Variation of Ip as a function of voltage scan rate.
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In addition to the reversible descriptions for CV experiments, the 
voltammetric behaviour resulting from electron transfer is summarised with a 
coupled homogeneous reaction mechanism. The notation uses E for an 
electrochemical step often resulting in a peak and C for a chemical step where 
new products are formed. The simplest mechanism is EC where X is oxidised 
or reduced to form Y, which then forms a new product in solution 
(Figure 2-10):
X(aq)+ e'*-> Y(aq) E
Y(aq) /cEc—> products C
- 0.1 0.0 0.1 0.2 0.3 0.4 0.5
Potential / V
Figure 2-10: Cyclic voltammogram demonstrating an EC mechanism.
The EC mechanism occurs where a reaction species ‘Y’ is formed at the 
electrode surface, if it is unstable it will decay with a rate constant of /cEc. The 
analysis of the reaction kinetics can be investigated by varying the potential 
sweep rate. The next process is the EC’ where the prime represents a 
catalytic process (Figure 2-11):
X ( a q ) + e  < - » Y ( a q )
Y(aq) + Z _> X + products
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The catalytic process occurs as the product of the electrode reaction reacts 
with a substrate molecule in solution resulting in Y being oxidised back to X. 
This mechanism is usually recognised from the change in profile with 
increasing [Z], due to the increasing steepness of the peak formation.
Increasing Z
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6
Potential /  V
Figure 2-11: Cyclic voltammogram demonstrating an EC' mechanism.
Another homogenous reaction is the ECE mechanism (Figure 2-12):
X(aq)+e"<-> Y(aq) E
Y(aq) -> Z C
Z + e" ++ A E
This is an extension on the EC reaction, the initial electrochemical and 
chemical steps are identical to the EC reaction. However, the product formed 
‘Z’ is now also electroactive, the reaction where A is formed usually produces 
a new peak.
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Figure 2-12: Cyclic voltammogram demonstrating an ECE mechanism.
2.5.2. Square Wave Voltammetry
Squarewave voltammetry is popular because it has a broader dynamic 
range and a lower limit of detection, it also measures current as a function of 
time. This technique was primarily used as an accompaniment to cyclic- 
voltammetry. The Faradaic peaks are observed at similar potentials to the CV 
technique but with better peak resolution (see inset Figure 2-13). There are 
two key parameters to consider when setting up a SW experiment, namely, 
the frequency and potential range. The square wave is a sequence of 
potential steps (Figure 2-13), where the recorded current is the difference 
between the current of the forward and reverse pulses (high and low current 
measurements). This technique allows higher scan rates to be used whilst 
maintaining good signal to noise ratio and improved peak resolution.
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Figure 2-13: Squarewave voltammetry schematic, inset: Current response in a square 
wave experiment.
The interval time is determined by the reciprocal of the square wave frequency 
therefore:
Scan rate oc frequency
2.6. Fixed Potential Chronoamperometry
Chronoamperometry is a very important technique employed for many 
electrochemical sensors due to the simple technology required. Unlike 
voltammetry this technique steps the potential of the WE instantaneously 
between the values Ei and E2 with a ‘pulse’ typically leading to the conversion 
of reactant to product at the electrode surface (Figure 2-14).
----------------► 0 5 10 15 20 25
Tim e/s -nme/s
Figure 2-14: A: Schematic of applied potential in a chronoamperometric experiment, 
B: Current response in a potential step experiment.
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Immediately following the step, a large current is detected which falls steadily 
with time. The large current occurs due to two different components: 
capacitance and Faradaic. The capacitance occurs because the electrode 
surface prior to applying the potential will have a net positive or negative 
charge, whilst the solution has a mixture of positive and negative ions. When 
the potential is applied, any analyte in the vicinity of the electrode is oxidised, 
leading to a sharp increase in the current. Following this there is a steep drop 
due to a depletion of new material, the current then drops more gradually as 
the experiment is diffusion controlled (Figure 2-14). The Cottrell equation 
which is derived from Fick’s diffusion law, describes the current response as a 
function of time:
|/|=  nFMf[C\
11 j^/2 *1/27i r
Where |i | is the current measured at time t (s) at the electrode of area A 
(cm2), which is directly proportional to [C] (mol / cm3) the bulk concentration of 
the electroactive species, and D is the diffusion coefficient (cm2 /  s).
2.6.1. Rotating Disc Electrodes
(
Hydrodynamic electrodes are used to allow convection to occur within a 
controlled environment. There are three reasons to desire convection; as 
explained previously to overcome natural convection to force fresh material to 
the surface of the electrode but also to decrease the diffusion layer at the 
surface of the electrode. To improve the mathematical prediction of the 
experiment Rotating Disc Electrode (RDE) aim to obtain laminar flow. In a 
laminar flow the solution moves smoothly in layers along constant directions. 
RDE experiments have a central WE, which is designed to be in a uniform
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cylindrical sleeve -  usually made of Teflon, which can be rotated at a constant 
speed. The rest of the electrode set-up can be viewed in Figure 2-15.
^ ^ ^ ^ - T e f lo n  Lid
------------- RE-----
Rotating
WE Solution
Figure 2-15: Cell set-up for the Rotating Disc Electrode Experiment.
The rotation within the solution forces a convection where material at the 
electrode is forced outwards and new material is pulled up from the centre of 
the solution to the electrode surface thus supplying a steady replenishment of 
material to the electrode surface with a predictable laminar flow pattern as 
demonstrated in Figure 2-16 (A). The Levich equation is used to predict the 
variation in the transport limiter current (iUm) as a function of the rotation speed 
(w), where B is electroactive material:
ium = 0.62nFA[B]buikDB2,3BV‘1,6aj1/2 
A plot of the transport-limited current against the square root of rotation speed 
should yield a straight line, which passes through the origin as in Figure 2-16 
(B).
A B
4 ^  Disc "^Rotation
I
Figure 2-16: (A) Demonstration of the laminar flow lines for an RDE experiment. (B) A 
Levich plot for an RDE experiment.
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3 Uric Acid Analysis: Characterisation
The electrooxidation o f uric acid (UA) in the presence o f nucleophilic species is shown to 
produce conjugates that can aid our understanding of antioxidant interactions and also 
provides opportunities for advancing electroanalytical detection strategies for purines.
3.1 Introduction
Electrochemistry has been widely employed to investigate the oxidative 
transformations that urate can undergo. Products of UA electro-oxidation have 
been found to mirror those resulting from enzymatic peroxidase and H20 2 
catalysis. An abridged reaction pathway detailing the oxidation of urate is shown 
in Figure 3-1 [1].
o
+2e‘+ 2 H + -2e--2H+
O 9 O H 9 OH
H 20  HN
J
o
+ 2 e + 2 H + + H h
y= O  + C 0 2
Figure 3-1: Electrochemical mechanism for UA [1].
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UA (a) is oxidised in a 2e', 2H+ process leading to the production of a reactive 
dimine species (b). This undergoes nucleophilic attack from water producing an 
imine alcohol (c) that, after the addition of a second water molecule, undergoes 
an intra-molecular degradation to allantoin (g) [1]. Electrogenerated dimine and 
its subsequent reaction with other nucleophilic species could therefore be used 
as a probe through which the physiological interactions of UA can be investigated 
and, as such, the work described in this chapter has sought to explore the 
capacity for other nucleophilic species to attack the dimine (b) intermediate. Two 
objectives were sought:
• To assess the potential impact of urate oxidation on other physiological 
species, and
• To investigate the feasibility of functionalising the urate centre in - situ with 
a new redox tag.
If the latter is possible, it could be used as a valuable marker in probing metabolic 
pathways and also provide an unambiguous label through which urate is 
quantified and complement the quinone markers used in thiol analysis [2-4].
3.2 Sample Preparation and Experiment Set-Up
All reagents were of the highest grade available and were used without 
further purification. Each reagent solution, with the exception of UA, was 
prepared daily in BR buffer before any experimental analysis, UA was prepared 
in 0.1 M NaOH. Electrochemistry was conducted using an Autolab potentiostat, 
(50 mVs"1). A three electrode configuration was adopted throughout with a glassy
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carbon electrode, Pt wire electrode and Ag/AgCI (3M KCI) as the working, 
counter and reference electrodes respectively.
3.3 Preliminary Characterisation of Uric Acid
The majority of the sensor work will be carried out at pH 7; UA is an anion at 
this pH because it has a pKa of 5.75, although initial characterisation of UA was 
carried out across the pH range. An initial scan of UA was carried out across a 
wide potential range to reveal all of the oxidation and reduction peaks at a 
polished glassy carbon electrode vs. Ag/AgCI (see Figure 3-2).
la 0.34V
10pA
Anion at pH 7Uric Acid
i b 0.29V
+H
I I C -1.0V
-1.5 -1.0 -0.5 0.0 0.5
Figure 3-2: Cyclic voltammogram of 1mM UA in Britton Robinson’s buffer at a glassy 
carbon electrode vs. Ag/AgCI at pH7, sweep rate 200 mVs'1.
There is one oxidation peak Ia and two reduction peaks Ib and I IC. The first 
step of the electrochemical mechanism for UA is responsible for I a, a 2H+, 2e‘
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reaction corresponds to the dimine compound Figure 3-1, b. The reduction of 
this unstable species produces lb forming a quasi-reversible peak with Ia but is 
only seen with fast scan voltammetry. The disappearance of this compound is 
due to a second anionic intermediate imine-alcohol species produced after 
nucleophilic attack from water and an -OH addition onto C5 (see Figure 3-1, c). 
The second reduction peak Hc is from the reduction of the intermediate imine- 
alcohol in a 2e", 2H+ reaction across the C4=Ng double bond that produces a 
dihydro species (see Figure 3-1, d). The imine -  alcohol further decays down to 
the 4,5 diol species (see Figure 3-1, e), which, in turn breaks down to allantoin 
and CO2 (see Figure 3-1, g).
3.3.1 Adsorption of Uric Acid
Another aspect of UA oxidation is that it adsorbs strongly at carbon 
electrodes [1] and at metal electrodes [5]. It is probable that UA oxidises only 
after it has adsorbed onto the electrode surface. This adsorbtion can inhibit the 
charge transfer of other analytes to the electrode. Experiments were carried out 
to investigate the adsorbtion of UA onto a glassy carbon electrode (GCE) 
(Figure 3-3). Initially a scan of the polished GCE was carried out in pH1 buffer to 
ensure that there was no UA present which was counted as the blank Figure 3-3. 
Next the electrode was left to stand in a 300 pM solution of UA for 10 min. After 
this the electrode was rinsed with deionised water and scanned in the blank 
buffer solution at 50 mVs"1 which was scan a, Figure 3-3. Finally, a scan was 
carried out with the GCE, after polishing, in the 300 pM UA solution for 
comparison, this was scan b, Figure 3-3. The presence of a UA peak in (a)
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proves that UA does adsorb onto the electrode surface although it is not as 
intense as (b).
0.030 -
Scan b - Voltammogam of UA 
Scan a - Adsorption 
Blank
0.025 -
0.020 -
300 pM UA solution 
in pH1 buffer 
at 50 mV/s< 0.015 -
c
CD
i—
^  0.010 -
0.005 -
0.000 -
0.5 0.6 0.7 0.8 0.9 1.0
Potential / V
Figure 3-3: Cyclic voltammogram showing adsorption at a GCE using a 300 pM UA 
solution (pH1).
3.3.2 Scan Rate Variation
The scan rate was investigated for UA to check the quasi-reversibility 
character previously described with the I a, and I b peaks (Figure 3-4).
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Potential / V
Scan rate 
mV/s
Figure 3-4: Cyclic voltammogram showing adsorption at a GCE using a 300 pM UA 
solution (pH1).
The calibration graph (see Figure 3-4, b) shows that the Ia peak shifts with 
increasing scan rate. Initially this is an irreversible peak but at higher scan rates 
the reduction peak can be detected. The Ib peak can only be observed at high 
scan rates as it is necessary to out run the breakdown of the imine -  alcohol to 
the more stable diol.
3.3.3 Uric Acid Oxidation and Changing pH
The oxidation of UA was investigated at a pH range from 2 - 1 2  
(Figure 3-5). As the buffer is adjusted in increments from acidic to a basic pH the
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I a shifts to increasingly more negative potentials, and vice versa, the peak shifts 
to more positive potentials as the buffer is adjusted to acidic pHs.
pH 12 
pH 10 
pH 8 
pH 7 
pH 6
10
8.0
pH 2
6.0
4.0
2.0
0.4
0.0 0.2 0.4 0.6 0.8
Potential / V
Figure 3-5: Cyclic voltammogram showing the response at a GCE using a 100 pM UA 
solution at varying pH at 50 mVs'1.
The peak height is also affected by a pH change with a difference of 8.22 
pA from the extreme pH peaks. This can be explained by the change in surface 
adsorption ability of the UA. At acidic pH’s the urate and the surface -COOH 
groups are both protonated, therefore the UA is able to adsorb to the surface. 
However, at more basic pH’s the UA is an anion, as indicated previously there is 
a negative charge on the electrode surface from -COO* groups. Hence the 
electrode begins to repel the UA from the surface and it is no longer able to 
adsorb leading to a decrease in the peak height.
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3.4 Uric Acid interactions with Analogous Analytes
Cyclic voltammetry was used as the primary technique for characterising 
any redox reactions, which occurred in the presence of UA with similar analytes 
e.g. ascorbic acid (AA) and thiols. The first analyte, which was investigated 
alongside UA was AA, which is the greatest interferent candidate with an 
oxidation potential similar to UA. Conversely, it is also a biomarker for several 
clinical conditions so by using a technique, which detects AA yet still successfully 
separating it from UA leaves an opportunity for development of a multianalyte 
sensor for UA and AA. These experiments were carried out in BR buffer at pH7. 
A spike of UA (300 pM), was initially added to the solution and then AA was 
added in smaller aliquots. Between each addition of aliquot to the buffer the 
solution was stirred and then allowed to rest before each scan.
25.0-1 OHOH
HO OH
20.0 -
Ascorbic Acid
15.0- 300 pM AA 
400 pM UA
Increasing
AA
-  10.0 -
-5.0
0.2 0.0 0.2 0.4 0.6 0.8
Potential / V
Figure 3-6: Cyclic voltammogram of the response of AA added to UA at a GCE in 15ml BR 
pH7 at 50 mVs'1.
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AA has a 2e, 2H+ reaction at 0.18 V oxidising at a lower potential to UA 
(Figure 3-6), and unlike UA it does not have a sharp adsorption peak, which at 
low concentrations makes it difficult to detect.
Although the two oxidation peaks are well defined here, there is barely 
40 mV between them. There is however, no other interaction between the two 
peaks. Thiols are also detected by electrochemistry at similar oxidation potentials 
to AA and UA. The most significant thiol is cysteine as a potential interferent to 
UA analysis. In the absence of urate, a single irreversible oxidation process is 
observed at +0.58 V for cysteine oxidation, which can be attributed to the 
oxidation of the RSH functionality to the corresponding disulphide (RSSR). In the 
presence of increasing concentrations of urate however the magnitude of the 
cysteine oxidation process was found to decrease markedly (Figure 3-7).
HO
SH
Cysteine
Increasing 
additions 
of UA
0
0
100 uM UA
200 |iM Cysteine
-2.0
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
Potential / V
Figure 3-7: Cyclic voltammogram showing the response of cysteine added to UA at a GCE 
in 15 ml BR pH7 at 50 mVs 1.
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The oxidation of urate occurs at potentials that are significantly less positive than 
those required for thiol oxidation. The RSH functionality can therefore undergo 
nucleophilic addition to the electrogenerated uric di-imine (II) resulting in the 
production of a purine-S-R conjugate. This is electrochemically inactive within the 
potential window investigated as no other electrode processes were observed. 
Thus, as the potential is increased to more positive values, the magnitude of the 
cysteine is depressed as a consequence of its reaction with the uric di-imine. 
Increasing concentrations of urate effectively lead to the production of more 
di-imine, which in turn consumes more RSH through an EC mechanism. Overall, 
the direct RSH oxidation is effectively removed. The interaction between oxidised 
urate and other nucleophiles was extended to 5-aminosalicylic acid (5-ASA), 
(a common anti-inflammatory). This compound is capable of quasi-reversible 
electrochemical behaviour (2e‘, 2H+ transitions) at a GCE and possesses an 
aromatic amine functionality that will be largely unprotonated at physiological pH. 
The aim was to determine whether or not the aromatic amine could attack 
electrogenerated urate di-imine with the subsequent conjugate possessing a 
redox profile different from either parent. Cyclic voltammograms detailing the 
electrode response towards UA in the presence of increasing concentrations of 5- 
ASA are shown in Figure 3-8. The oxidation of 5-ASA was initially observed as a 
shoulder immediately before the oxidation of the UA. A new redox process was 
however observed at +0.51 V. This peak was absent from the parent redox 
profiles and was found to increase with increasing additions of 5-ASA to the UA 
solution and vice versa. This was attributed to the redox behaviour of the 
conjugate UA-5-ASA.
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Figure 3-8: Cyclic voltammogram showing the response of 5-ASA added to UA at a GCE in 
15 ml BR pH7 at 50 mVs \
The conjugate species can be seen to exhibit quasi-reversible electrochemical 
behaviour and could be attributed to the oxidation and reduction of the purine 
attached ASA component as indicated in (Figure 3-9).
COOH COOH
OH
■2e, -2H
I
Puri ne
+2e.+2H‘
I
Purine
Figure 3-9: Redox transitions attributed to the urate-5-ASA conjugate.
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The nucleophilic character of the 5-ASA conjugate was corroborated by 
re-examining the response of 5-ASA in the presence of urate within a solution 
buffered at pH 4. The acidic conditions would protonate the amine group, thus 
removing the nucleophilic character. The experiment was repeated with a UA 
spike (300 pM) and additions of 5-ASA. At the low pH, no oxidation peak was 
observed after the UA oxidation peak (Figure 3-10), there was a shift in oxidation 
potentials of 5-ASA and UA due to the pH shift as discussed in section 3.3.3.
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Figure 3-10: Cyclic voltammogram showing the response of 5-ASA added to UA at a GCE 
in 15 ml BR pH4 at 50 mVs'1.
3.4.1 Nucleophilic Characterisation
The interaction of electro-oxidised urate with HQ (hydroquinone) was 
assessed to see if it has any interactions with the former analyte, which might
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create a new redox peak. HQ was chosen for its lack of nucleophilic character yet 
strong redox reaction. There was clear separation of UA and the HQ oxidation 
peak which was observed at 0.16V, but no other interactions were produced 
Figure 3-11. This is as expected if the nucleophilic functionality is required for the
electrochemical tagging of UA.
Hydroquinone
10
Increasing
HQ
5
0
300 pM HQ 
300 pM UA
■5
-0.1 0.0 0.1 0.2 0.3 0.4 0.5
Potential / V
Figure 3-11: Cyclic voltammogram showing the response of HQ added to UA at a GCE in 
10 ml BR pH7 at 50 m Vs1.
Paracetamol (PA) was assessed as this oxidises at a similar potential to UA and 
is often found in physiological samples. The presence of the acetyl group on the 
nitrogen of the acetoamidophenol would effectively remove its nucleophilic 
character and hence should prevent its reaction with the uric di-imine. A similar 
experiment was carried out with the PA oxidation peak observed at 0.39 V. As 
such, no new redox peak was observed Figure 3-12.
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Figure 3-12: Cyclic voltammogram showing the response of PA added to UA at a GCE in 
10 ml BR pH7 at 50 m Vs1.
Evidence to corroborate the addition of the 5-ASA to the oxidised purine 
was provided through examining the response to 1,4-phenylenediamine (1,4-pd). 
The 1,4-pd and PA exhibit similar redox behaviour to that of 5-ASA in the 
absence of urate but only the former gave responses analogous to those 
observed in Figure 3-8 when urate was present. The 1,4-pd was observed at 
0.18 V and the new oxidation peak was observed at 0.52 V as shown in 
Figure 3-13. Overall, the experiments strongly suggest that a compound with 
nucleophilic character can be used to tag UA in solution producing a new 
oxidation peak which potentially allows separation and detection of UA from
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analytes that oxidise at similar potentials. Alternatively, it provides a method of 
tagging nucleophilic substances like 5-ASA with a biochemically safe technique.
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Figure 3-13: Cyclic voltammogram showing the response of 1,4-pd added to UA at a GCE 
in 10 ml BR pH7 at 50 mVs'1.
The final step of the investigation was to assess whether the tagging process still 
occurred in the presence of AA. The presence of AA was not found to impede the 
formation of the conjugate (Figure 3-14) and hence it could be envisaged that the 
in-situ tagging of the purine within physiological fluids could be achieved. AA 
does have a similar oxidation potential to 5-ASA, which suggests that multi­
analysis of AA and UA might not be possible using this technique.
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Figure 3-14: Cyclic voltammogram showing the response of 5-ASA added to equimolar UA 
and AA at a GCE in 10 ml BR pH7 at 50 mVs'1.
3.5 Purine Investigation
There are many other purines, which play a vital physiological role, 
including the precursors to UA, xanthine (XA), hypoxanthine (HX), and DNA 
bases adenine (Ad) and guanine (Gu) as shown in Figure 3-15. Urate has the 
lowest oxidation potential of these purines; however, they all have observable 
oxidation peaks at a GCE and similar characteristics to UA. Any methods of 
detection for UA that are established could be used as a model to detect other 
purines. It could be envisaged that with a sophisticated enough working electrode 
(WE) material a biosensor could monitor multiple purines simultaneously with one 
single strip as long as the peaks are well separated. This would allow a multitude 
of other clinical conditions to be monitored with UA multitasking as an internal 
standard and biomarker in its own right. XA and HX are most commonly detected 
in the food industry to determine food aging [6-8]. However, they are also
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detected alongside UA and other purines as biomarkers particularly when looking 
for early onset of disease in children [9] and N-Methylated xanthines such as 
caffeine, theophylline and theobromine are central nervous system stimulants.
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Figure 3-15: Schematic of purine degradation.
Both XA (Figure 3-16) and HX (Figure 3-17) have adsorption oxidation peaks 
similar to UA, with oxidation peaks of 0.78 V and 1.16 V, respectively.
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Figure 3-16: 50 pM additions of XA to 10 ml BR pH7 using SW, 25 Hz. Inset: 50 pM additions 
of XA to 10 ml BR pH7 using CV, at 50 mVs"1.
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Figure 3-17: 50 pM additions of HX to 10 ml BR pH7 using SW, 25 Hz. Inset: 50 pM 
additions of HX to 10 ml BR pH7 using CV, at 50 m Vs1.
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The role of Ad and Gu as the DNA bases is probably their prime role 
biochemically however, adenine is also found as a component of many 
coenzymes including nicotinamide adenine dinucleotide phosphate (NADP+), 
nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide (FAD). 
Adenine, guanine and their derivatives are involved in a diverse range of 
chemical processes and therefore a simple detection system for purines would be 
very desirable. Both Gu (Figure 3-18) and Ad (Figure 3-19) have clear oxidation 
peaks, which occur from adsorption at the electrode surface with potentials of 
0.79 V and 1.08 V, respectively. The oxidation peaks for HX and Ad do not 
demonstrate such sharp adsorption peaks as UA, this is possibly because of their 
high overpotential.
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Figure 3-18: 50 pM additions of Gu to 10 ml BR pH7 using SW, 25 Hz. Inset: 50 pM 
additions of Gu to 10 ml BR pH7 using CV, at 50 m Vs1.
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Figure 3-19: 50 pM additions of Ad to 10 mi BR pH7 using SW, 25 Hz. Inset: 50 pM additions 
of Ad to 10 ml BR pH7 using CV, at 50 m Vs1.
Multi-analysis was investigated with different combinations of the purines 
to determine whether there was good peak separation in a mixture. Whilst it is 
possible to separate out combinations of UA with the DNA bases or UA with its 
precursors HX and XA (Figure 3-20), it is not possible to separate out a mixture 
of all the purines because of the overlap in potential between Gu and XA and 
similarly Ad with HX.
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Figure 3-20: 150 pM additions of purine to 10 ml BR pH7 using SW, 25 Hz, using GCE.
3.5.1 Reduction Technique for Tagging Purines
A squarewave technique was used to see whether these purines undergo 
nucleophilic addition with 5-ASA. The technique was employed to improve the 
chances of tagging occurring. The experiment involved adding the purine and 
5-ASA to the solution and then applying a high potential to allow oxidation to 
occur. The scan was then decreased to a negative potential and the reduction 
peaks were observed. The reduction profile for 5-ASA has four peaks at -0.12V, 
0.08V, 0.23V and 0.45V (Figure 3-21). This technique was first tested with UA to 
ensure that tagging still occurred using this process and determine the peak 
potential of the conjugate.
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Figure 3-21: 300 pM 5-ASA profile in 10 ml BR pH7, SW, 50 Hz.
There was a single reduction peak for UA at 0.30 V (Figure 3-22). When the 
technique was tested with UA and 5-ASA a new reduction peak was observed at 
0.58 V, which was attributed to the UA—5-ASA conjugate, thus confirming that 
the reduction method worked successfully (Figure 3-23).
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Figure 3-22: 300 pM UA profile in 10 ml BR pH7, SW, 50 Hz.
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Figure 3-23: 50 pM additions of UA to 300 pM 5-ASA and 10 ml BR pH7, SW, 50 Hz.
This technique was tested with Ad and Gu. The only other conjugate formed was 
with Gu, which has two reduction peaks at 0.32 V and 0.77 V (Figure 3-24).
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Figure 3-24: 300 pM Gu profile in 10 ml BR pH7, SW, 50 Hz.
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The peak assigned to the conjugate of Gu —  5-ASA is at 0.58 V and does not 
occur on either of the parent reduction profiles (Figure 3-25).
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Figure 3-25: 50 \iM additions of Gu to 300 pM 5-ASA and 10 ml BR pH7, SW, 50 Hz.
However, a small amount of overlapping does occur with the conjugate peak and 
the 5-ASA peak at 0.45 V that cannot be resolved from the conjugate peak. The 
small Gu peak at 0.32 V is barely visible in the mixture. This may be because it 
does not have the same adsorbtion behaviour that is exhibited by the reduction 
peak at 0.77 V.
The most likely reason for Gu and UA to undergo the tagging reaction with 
5-ASA is the carbonyl group on C6, which is electron withdrawing from the C5, 
subsequently a 5+ charge at C5 allows nucleophilic addition to occur. In contrast 
Ad has the amine group, which will not create the same 5+ charge, thereby 
blocking the potential for any nucleophilic addition (Figure 3-26).
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COOH COOH
OHOH
H —H —
Tagging can occur
Guanine Uric Acid
Insufficient electron with-drawing group
H
Adenine
Figure 3-26: Representation of tagging theory onto UA and Gu, no tagging occurs with Ad.
Confirmation that the Gu — 5-ASA conjugate was attributed to nucleophilic 
addition was tested by repeating the experiment at pH 5 (Figure 3-27).
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Figure 3-27: 50 pM additions of Gu to 300 pM 5-ASA and 10 ml BR pH5, SW, 50 Hz.
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At the low pH the 5-ASA peaks shifted to 0 V, 0.12 V, 0.34 V and 0.63 V. The Gu 
peaks shifted to 0.48 V and 0.88 V. There was no conjugate peak observed at 
the low pH confirming that this was a nucleophilic addition.
3.6 Nucleoside Investigation
The electrochemical profile of the nucleosides Ads (Adenosine) and Gus 
(guanosine) were investigated to assess whether this technique could be used to 
probe more complex biochemical processes using a simple set-up and whether 
they could be tagged with 5-ASA. Clear redox reactions observed using a simple 
experiment set-up would demonstrate the potential that electrochemistry has to 
be used in a clinical environment and as an alternative to expensive laboratory 
techniques e.g. HPLC. Both Ads (Figure 3-28) and Gus (Figure 3-29) 
demonstrated clear oxidation peaks at 1.29 V and 0.98 V, respectively.
Adenosine 1.29 V20,8 n h 2
HO-6
HO OH
4
1.2
Potential / V
1.3
2
0
0.6 0.8 1.0 1.2 1.4
Potential / V
Figure 3-28: 50 pM additions of Ads to 10 ml BR pH7 using SW, 25 Hz. Inset: 50 pM 
additions of Ads to 10 ml BR pH7 using CV, 50 mVs"1.
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Figure 3-29: 50 pM additions of Gus to 10 ml BR pH7 using SW, 25 Hz. Inset: 50 pM 
additions of Gus to 10 ml BR pH7 using CV, 50 mV'1.
Tagging did not occur, this could be attributed to the sugar present in the 
structure shielding it from nucleophilic tagging.
3.7 Conclusion
These results have important ramifications for our understanding of the in-vivo 
regulation of anti-oxidant thiol concentrations as the oxidation of the purine may 
clearly induce the depletion of the thiol. This also impacts on the implementation 
of voltammetric techniques aimed at the sequential detection of these species. As 
urate will inevitably be at substantially greater concentrations than those of the 
thiol, it is likely that the thiol will be effectively removed in the course of the scan 
leading to a gross under-estimation of the thiol concentration. Nucleophilic 
addition however could be analytically exploited for the detection of urate. 
Quantification of urate is often hindered by the close overlap of ascorbate and
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many strategies have evolved to aid their resolution [2, 3, 10-12]. The addition of 
5-ASA and phenylene diamine redox components to the purine represents the 
first stage in the search for new labels that could aid discrimination. In addition to 
the advantage of tagging demonstrated here is the possibility of using 
electrochemistry to investigate biochemical pathways in more depth as many 
involve purine derivatives, providing a competitive advantage over current 
techniques because electrochemistry is a commercially viable process without 
the need of highly qualified staff to run an experiment, usually with disposable 
components which has a high priority in a medical environment.
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4 Carbon Fibre Laminate Electrodes
The primary aspect of this research is discovering new techniques and materiais 
for uric acid (UA) detection, which are viable for clinical purposes. This chapter 
presents the research carried out with carbon fibre (CF) matting, which was 
encapsulated with polyester through lamination to develop the basis of a 
disposable electrochemical sensor. Two designs were assessed and 
characterised using conventional physical and electrochemical methods. 
Modification of the laminate assembly to alter the response characteristics of the 
sensor has been described and shown to aid the detection of urate. The clinical 
efficacy of the disposable laminate electrode is evaluated through inter-laboratory 
validation using human physiological samples, namely serum and plasma.
Uric acid has long been recognised as a potentially significant diagnostic 
aid in the identification and treatment of cardiovascular disease [1], hypertension 
[2,3] and renal disease [4,5]. There is a substantial body of evidence to support 
the assumption that urate has an independent role in the pathogenesis of these 
conditions [6,7]. Pharmacological intervention to reduce urate concentration in 
such instances can have a significant influence on the clinical outcome. The 
administration of allopurinol has been shown to lead to significant decreases in 
mortality rates in postoperative coronary contexts and effectively reversed 
endothelial dysfunction in heart failure subjects [8]. Improved cardiovascular 
mortality in the Losartan Intervention For endpoint reduction in hypertension 
(LIFE) trials has also been attributed, in part, to the lowering of UA
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concentration [3]. Through being able to monitor the concentration of urate, it 
could be anticipated that predictive-preventative treatments could be employed at 
an early stage that could remove the potential for, or at least lessen the severity 
of, future complications.
The need for early identification and treatment lies in the fact that a 
number of studies have indicated that UA may be an important initiator of 
hypertension but may have little influence in the subsequent maintenance of the 
condition. Alterations to the intra-renal microvasculature initiated by 
hyperuricaemia, appears to ultimately lead to a salt sensitive hypertensive state 
that becomes largely independent of urate concentration [9-11]. The
administration of allopurinol has been shown to reduce both serum urate and 
blood pressure in adolescents and advances the case for the childhood 
screening of hyperuricaemia as a preventative measure [12,13]. Urate
measurement currently requires referral to centralised laboratories. Therein lies 
the problem as very few of us have the time to travel regularly to appointments,
Ejecfrodp usua Y^ on designated days and times set by the clinic, 
Contacts wjthout ^ impacting on usual routine. However, it would be
highly beneficial to have a simple device that could allow the
patient or a health care assistant / health visitor to regularly
Ag|AgCI
Carbon screen and access an immediate response [14,15]. The 
most significant example of current point-of-care analysis is
Figure 4-1: Screen g|UCOse testing for diabetes. Screen printed electrodes 
printed electrode.
(SPE) are widely used in biomedical applications and form 
the backbone of many of the commercial glucose sensors used in home
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diagnosis (Figure 4-1). However, their use for the direct electrochemical 
detection of analytes within blood is often hampered by poor resolution and 
sensitivity because of overlapping signals from other electroactive compounds 
like ascorbic acid (AA) and UA [16]. This is overcome via a host of different 
techniques including mediators to decrease the required applied potential, 
surface barriers to eliminate interferents and electrochemical modification to repel 
analytes. The approach taken here has been to extend current technology to 
detect multiple analytes at micromolar concentrations whilst still employing 
economical materials with a simple detection process. The route taken here was 
to use carbon fibre (CF) composite technology (Figure 4-2) as a new disposable 
sensing substrate for the direct determination of UA in serum. CF has been 
shown to provide a highly conductive substrate for use in a wide variety of 
electroanalytical investigations -  particularly for in-vivo microelectrode studies of 
neurotransmitters [17-19].
Figure 4-2: Scanning electron micrographs of the CF framework.
The key questions that need to be addressed are whether this material can 
exhibit the required sensitivity for purine analysis (principally urate) directly within
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serum and thereby serve as an alternative to the colorimetric enzymatic method 
currently used.
4.1 Methodology
The electrode is constructed by encapsulating the brittle CF within a thermal 
lamination pocket of insulating layers of a resin backed polyester film 
(Figure 4-3).
<V X85 lOOjOTi WD 16.7mm
P Carbon Fibre Matting Polyester Encapsulant
' ‘■•ri.vtfasi'vH
 ^ ~ I
Laminate Assembly 
Copper Contact
Exposed Electrode
Upper Sleeve------
Carbon Fibre Mat ■ 
Bottom Sleeve —
Figure 4-3: Scanning electron micrograph of the CF - laminate interface. Inset: Schematic 
of prototype electrodes.
The film is pre-punched to expose a defined working surface area of the 
electrode (5 mm diameter) with the laminate casing providing a degree of 
mechanical support but which maintains sufficient structural flexibility that allows 
easy manipulation of the strip design. Thermal activation of the resin induces the 
adhesive to permeate between the fibres directly exposed to the covering case 
but retain an active surface at the exposed window. Two design approaches were 
taken, firstly the hole punch method as previously described (Figure 4-4).
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Bottom laminate sheet_ 
approx 5cm by 0.9cm
Hole punched into 
bottom laminate strip
Copper strip
Carbon fibre mat 
Figure 4-4: Schematic of the hole punch CF electrode.
Top laminate strip 
approx 4.5cm by 0.9m
Hole punched in 
top laminate sheet
Copper strip
Bottom laminate sheet 
approx 5cm by 0.9cm-
Top laminate strip 
approx 4.5cm by 0.9m
Drilled hole through 
laminated electrode
Carbon fibre mat
Figure 4-5: Schematic of the microtube CF electrode.
Secondly the whole may be punched along with the encapsulating sheath to form 
a microtube electrode. In the latter case, the surface of the CF is exposed within 
the walls of what can be termed a detection well (Figure 4-5).
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4.2 Experimental Set-up
All reagents were of the highest grade available and used without further 
purification. Stock solutions of UA (typically 10 mM) were prepared in 0.1 M 
NaOH. All other solutions were prepared using Britton-Robinson buffer (BR) 
(acetic, boric and phosphoric acids - each at a concentration of 0.04 M) adjusted 
to pH7 through the addition of sodium hydroxide. Standard solutions were 
prepared in deionised water from an Elgastat (Elga, UK) water system and 
refrigerated when not in use. Toray CF cloth was purchased from E-Tek Inc 
(USA) and used as received. Lamination pouches (Rexel UK) were a commercial 
stationery variety with a film thickness of 75 pM each side. Copper shielding tape 
(100 pM thick, adhesive backed) was obtained from RS Electronics. 
Electrochemical measurements were conducted using a //Autolab type III 
computer controlled potentiostat (Eco-Chemie, Utrecht, The Netherlands) using a 
three electrode configuration consisting of the CF assembly working electrode, a 
platinum wire counter electrode and a Ag | AgCI (3M Cl ) half cell reference 
electrode (BAS Technicol, UK).
4.2.1 Clinical Samples
A clinical trial involving 6 male and 2 female volunteers, ranging from 21- 
40 years of age was conducted (refer to Appendix 1 for ethics approval). 
Samples of blood were obtained from the participants and analysed within three 
hours of extraction. Blood was collected in gel permeation Vaccutainers™ and 
then centrifuged at 3000 rpm for 10 minutes. The serum was withdrawn and used 
immediately for both electrochemical and spectroscopic analysis. Serum urate
Chapter 4: Carbon Fibre Laminate Electrodes 83
results were compared through inter-laboratory testing conducted within the 
biochemical laboratories at the Royal Surrey County Hospital NHS Trust. The 
UV-Vis spectrometry technique uses a Bayer® assay (Uricase / Peroxidase / 4- 
aminophenazone /N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline, Product 
No B01-4131-01) with endpoint detection at 520 nm.
4.2.2 UV-Vis Procedure
The reagent (1350 pi) was pipetted to a 1.5 ml epindorf, where 27 pi of the 
sample or calibration standard was then added. The liquids were mixed by 
agitating the Epindorf ™ that was consequently placed into the water bath held at 
37°C for 5 mins. The sample tubes were transferred to an ice bath to preserve 
the samples whilst each was analysed individually. The UV-Vis samples were 
analysed in quartz cuvettes with a 1 cm path length, at 520 nm (Figure 4-6).
Uricase
-► Allantoin + CO2 + H2C^Uric Acid + 0 2 + H£>
Peroxidase
2 H A  + 4-AAP +TBHB >  Quinoneimine + H20
4-AAP - 4-Aminoantipyrine
TBHB - 2,4,6-Tribromo-3-hydroxybenzoic acid0Oc
DjQ
O00n
<
Increasing 
Uric Acid
0.4 -
500 700 800400 600
Wavelength /  nm
Figure 4-6: UV-Vis analysis of urine using Infinity™ reagent for UA analysis. Inset: 
Chemical reaction of the reagent with UA.
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4.3 CF Characterisation
Preliminary characterisation of the different electrodes was initiated with a 
simple redox couple versus an Ag/AgCI reference electrode in buffer solution. A 
cyclic voltammogram produced with the hole punch design in the presence of 
increasing additions of Ferrocyanide (Figure 4-6) demonstrated that this simple 
design is comparable to a GCE.
50 pM Ferrocyanide 
Blank
2
oZ5
o
1
•2
0.2 0.4 0.6 0.8- 0.2 0.0
Potential / V
Figure 4-6: Cyclic voltammogram detailing the response of a carbon mat laminate 
assembly to ferrocyanide.
However, with prolonged use the seal at the laminate -  CF edge does deteriorate 
over time leading to leaching of the solution into the rest of the electrode material 
producing a larger electrode area with less sensitivity. This is demonstrated in 
Figure 4-7 where the electrode was cycled constantly for 10 mins in buffer 
solution between -0.2 and 0.6 V, at which point the previous experiment was 
repeated with 50 pM additions of Ferrocyanide. The increased electrode area
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amplifies the peak heights but creates a noisy signal. If the electrode is 
continually cycled, the laminate seal breaks down leading to leaching of the 
solution to the copper connection.
10 -
— 50 pM Ferrocyanide
— Blank
<
a.
c
CDtaO
0.0 0.2 0.4 0.6
Potential / V
Figure 4-7: Cyclic voltammogram detailing the effects of delamination on an untreated 
laminate assembly to ferrocyanide.
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Figure 4-8: Cyclic voltammogram detailing the response of a mircotube laminate assembly 
to ferrocene carboxylic acid.
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This electrode material and design lend themselves comfortably to clinical testing 
as a disposable strip, where there would be no issue of prolonged use thereby 
avoiding breakdown of the seal. The microtube electrode was tested with 
Ferrocenecarboxylic acid (Fc(COOH)), which produced a limiting profile and 
current range in the order of nano amps consistent with microelectrode behaviour 
(Figure 4-8). Similar to the hole punch design, the microtube undergoes 
delamination over time resulting in macroelectrode behaviour as the electrode 
surface area increases.
4.3.1 Analyte Detection Capability
The suitability of the carbon electrodes for analyte detection was assessed 
predominantly using square wave voltammetry as it could be anticipated that the 
methodology would aid the resolution of discrete voltammetric signals [16]. 
Physiological samples are highly complex with a variety of different chemicals 
present even in minute samples. Catecholamines for example are also oxidised 
at low potentials and are potentially capable of overlapping with the urate 
electrode process. These are normally present at low concentrations (i.e. 
dopamine < 5 nM, epinephrine <5 nM, norepinephrine <5 pM) and would impart 
little to the overriding purine signal [20]. Ascorbic acid however, poses a 
considerable problem in that it is one of the few components present within 
biofluids that can be oxidised at potentials similar to that of urate and which can 
be present at relatively high concentrations (20-90 pM depending on dietary 
factor and physiological well being) [20]. A voltammogram showing the response 
of the CF assembly to equimolar AA/UA (300 pM, pH7) is shown in
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Figure 4-9, A. While qualitative discrimination between the two electrode 
processes is possible, extraction of a suitable baseline to gauge the 
concentration of UA is clearly not practical.
UA
0.83VAA
0.49V
UA
0.36 V
2 jjA
AA
0.03V
T
-0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2
Potential / V
Figure 4-9: Squarewave voitammograms detailing the response to 300 pM ascorbate/urate 
at A unmodified and B, pre-anodised CF.
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Many strategies have been employed to counter the effects of ascorbate and 
facilitate the quantitative measurement of urate and include enzymes [24,25], 
polymeric coatings [26,27] and surface pretreatments [28,29]. The latter has been 
employed here because it is simple yet effective. Carbon electrodes present a 
heterogeneous interface that bears carboxyl, phenolic and quinoid components 
(Figure 4-10), whose respective populations can be modified through application 
of large anodic or cathodic potentials [28,29] called anodisation (+2 V, 0.1 NaOH, 
15 min) this yields an improved response to both UA and AA, (Figure 4-9B). The 
overpotential is reduced to +0.36 V and +0.32 V for AA and UA, respectively. The 
major improvement however, relates to the peak resolution, 0.31 V, between the 
two analytes. The sensitivity towards UA is massively increased and a distinct 
baseline can be determined from which to quantify UA.
Figure 4-10: illustration of the various functional groups on the CF surface before 
anodisation.
A comparison between the urate response at the modified CF composite and a 
commercial SPE are shown in Figure 4-11.
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Figure 4-11: Squarewave voltammograms detailing the response to urate (300 pM, pH 7) at 
screen printed electrode (dashed line) and at the pre-anodised CF (solid line).
SPE’s are another form of composite consisting of carbon particles, binders, etc 
and form the backbone of current glucose diagnostics. The peak resolution 
obtained at the CF composite is significantly sharper than that observed with the 
SPE (the difference in current reflects the significant difference in electrode area 
between the two designs). More importantly, the peak position for the laminate is 
shifted cathodically by at least 130 mV, 190 mV in the case of UA allowing lower 
operating potentials to be used. The improved peak profiles for the laminate can 
be attributed to the homogeneous nature of the underlying fibre, which provides a 
highly conductive track upon which the current can pass and contrasts to the 
heterogeneous SPE ink. The advantage of using the anodised CF could include 
more complex systems where oxidation potentials are so high that peaks are not
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resolved clearly due to break down of the solvent. This situation has been 
demonstrated with a mixture of UA, X and HX, the latter oxidises at 1.24 V 
(Figure 4-12), at the same point where the solvent begins to break down, at low 
concentrations it would be difficult to detect using SPE.
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Figure 4-12: Squarewave voltammograms detailing the response to urate (300 pM, pH 7) at 
a screen printed electrode and inset: pre - anodised CF electrode.
However, using a CF electrode the overpotential is decreased and peaks are 
much sharper (Figure 4-12, Inset), demonstrating the potential these CF 
electrodes have for complex multianalysis.
4.4 Clinical Analysis
The viability of the carbon laminate assembly for use in the analysis of 
complex biofluids was investigated. The determination of urate within plasma and
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serum was assessed in collaboration with the local hospital. The clinical 
assessment was conducted through comparing the responses of the modified 
composite sensing strips with the conventional spectroscopic assay. There was 
no pre-treatment of the sample required beyond the centrifugal removal of the 
cellular components for the electroanalysis. In general, a 300 pL sample extract 
was placed within 8 pL of pH 7 buffer and squarewave voltammetry was carried 
out as before. The flow chart in Figure 4-13 demonstrates the typical schedule 
required in the laboratory for carrying out the UA analysis with each technique. 
The UV-Vis method is complicated because of the added need for incubation and 
cooling where enzyme reagents are used. This method is made more time 
consuming because of the preparation time required for labelling sample tubes, 
preparing accurate standards and warming/preparing instruments. This technique 
has added costs with the reagents and sample tubes. In comparison to the UV- 
Vis technique the standard addition method employed for the electrochemistry 
analysis was successful as it is matrix-matched the complex sample making it a 
robust process. The electrochemical technique could also save on time and cost 
which is essential if it is to compete with an established method of analysis.
Chapter 4: Carbon Fibre Laminate Eiectrodes 92
Whole Blood Centrifuged to obtain serum
Of,
%
SerumEppindorf
Reagent-
Mix
gently
Incubate
o
37 cwaterbath 5 min
Cool
in
icebath
12
5 min
UV
Analysis
RE
CEWE-
<■ Stirrer
Serum
Figure 4-13: Flow chart of the analysis steps required for UV-Vis and electroanalysis.
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The voltammograms resulting from the addition of an initial serum sample and 
subsequent additions of a urate standard are shown in Figure 4-14.
7 nM UA 
300 |.il Serum
_c
-10
Concentration / uM
t  10
0.2 0.60.0 0.3 0.40.1 0.5
Potential / V
Figure 4-14: Squarewave voltammograms detailing the response of pre-anodised laminate 
to serum urate (300 pL in 8 mL pH7) and the subsequent additions of a standard urate 
solution. Inset: Standard Addition calibration graph to determine urate level in serum.
The signal due to urate is very distinct at 0.38 V with the pre-anodisation of the 
fibre substrate providing an unambiguous baseline from which urate can be 
quantified. The process was repeated with plasma and near identical 
voltammograms obtained. In either case, the measurements were conducted in 
triplicate and provided an average urate concentration of 253 pM (%RSD = 6.4, 
N=3) and 259 pM (%RSD = 9.8, N=3) for the serum and plasma sample
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respectively. The detection limit for the urate within pH7 buffer at the preanodised 
fibre was 0.27 pM (based on 3S/N) and provides a linear response over the 
range 0.3 pM to 50 pM (Ipa (pA)= 1.28 [UA/pM] -  11.58, N=8, R2 = 0.99, based 
on a 5 mm diameter system). This low detection limit is comparable to many of 
the techniques compared in Chapter 1 where electrode modifiers and enzymes 
were used, where LOD ranged from 2.5 to 0.3 pM. There was good intra 
reproducibility with the strips, which was less than ±5%. This was tested by 
repeating the experiment up to four times, rinsing in-between and scanning in 
pH7 buffer to remove any adsorbed UA. The inter-repeatability had a much lower 
tolerance at ±25%. This can be attributed to the extemporized way in which the 
strips are produced and the inherent variations in the CF material. The inter-strip 
deviation was overcome with the adoption of standard addition protocols and the 
final results for serum and plasma responses were within 10%. A mini clinical trial 
was subsequently conducted through which the electrochemical responses were 
compared with the standard colorimetric (bienzyme) method. The trial focused on 
the analysis of serum as this represents the medium through which standard 
clinical biochemistry procedures relate and allowed direct inter-laboratory 
comparison with the hospital’s technique. The analysis was conducted as before 
but in duplicate and was analysed using a single urate addition to mirror a single 
point calibration required for near patient testing. The results are summarised in 
Table 4-1, where it can be seen that the electrochemical method compares 
favourably with the independent laboratory results.
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Subject
Laminate EC
Urate / pM
Colorimetric
M1 309 290
M2 300 320
M3 328 360
M4 348 310
M5 339 320
M6 399 390
F1 415 460
F2 274 290
Table 4-1: Comparison between the CF electrode and colorimetric methods for serum urate 
(300 pL) analysis. Analysis performed duplicate with a different strip used for each 
determination.
It could be envisaged that for future analysis an internal standard could be 
introduced to replace the use of calibration additions and overcome the 
deviations between strips. This would create a more robust method for more 
efficient clinical analysis.
4.5 Combinatorial Analysis
The aspiration for the strips was to construct a combined electrochemical system 
of all three electrodes for simple physiological testing (Figure 4-15). This would 
require small sample volumes, ideal for a patient who requires repeated testing. 
To investigate the feasibility of using a joint electrode system a dual technique 
was used with electrochemistry and UV-Vis to allow smaller sample volumes to 
be used. The thin laminate electrode, along with a large area lends itself to 
spectroelectrochemical studies where conventional indium tin oxide (ITO) glasses
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are not suitable. One application is for the study of biomolecular UV transitions 
such as those involving quinone intermediates.
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Electrode Layer 1 
Electrode Layer 2
Figure 4-15: Combined laminate design, assembly and sensor.
An integrated sensing assembly was developed comprising of three 
individually addressable CF layers. One layer forms the basis of the micro ring 
working electrode with another layer serving as the counter electrode. Silver was 
electrochemically deposited onto the third layer and then chloridised to form the 
silver/silver chloride reference system (Figure 4-16).
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Figure 4-16: Schematic of CF laminate electrode within a UV-cell.
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This complete electrode was assessed for its ability to analyse quinones. Initially 
hydroquinone was investigated, 2 ml pH7 buffer was added to the cell and then 
63 pM aliquots of hydroquinone were pipetted into the cell, the solution was 
agitated with a pipette to mix, in-between each addition. A scan was then run 
between -0.6 and 0.6 V where the oxidation and reduction peaks were observed 
at 0.36 V and -0.32 V, respectively (Figure 4-17). A similar system was then 
used to analyse the electrochemical reduction of benzoquinone to hydroquinone. 
The UV-Vis cell and electrode were set-up as demonstrated in Figure 4-17, and 
then 2 ml of buffer (pH7) was pipetted to the cell finished with a 125 pM aliquot of 
benzoquinone, the cell was then agitated to mix the solution.
<
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Figure 4-17: Scan of hydroquinone using a complete three electrode strip within a UV cell.
An initial UV scan was run of the cell prior to starting the electrochemical scan, a 
UV scan of the cell was then run every 30s whilst a cyclic voltammetric scan was 
run between -0.4 and 0.8 V (Figure 4-18).
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Figure 4-18: Electrode response to benzoquinone whilst being scanned by UV -  Vis.
Benzoquinone has an absorbance peak at 246 nm whilst hydroquinone absorbs 
at 288 nm. Figure 4-19 demonstrates the decrease in concentration of 
benzoquinone to hydroquinone which occurs when potential is scanning from 0.8 
V to -0.4 V. The peak at 244 nm can be seen to increase again as the potential 
begins to scan from -0.4 to 0.6 V, which mirrors the oxidation of hydroquinone 
back to benzoquinone. This is illustrated more clearly in Figure 4-20, a single 
voltammogram has its forward and reverse scans coloured separately to highlight 
the oxidation and reduction peak changes which are inversely mirrored by the 
UV-Vis scan of the peak at 244 nm.
Chapter 4: Carbon Fibre Laminate Electrodes 99
Initial BQ scan of 1.5 mM
UV scan of BQ and growing 
HQ after electro-oxidation
CD
CJ> 0.8"cz03
_ oo
CO
- Q<=C OH
OH
0.2“
24 0 2 6 0  2 8 0  
W a v e le n g th  / nm
3 0 0200 220 320 3 4 0
Figure 4-19: UV-Vis response to benzoquinone whilst being electrochemically reduced.
Hence, if we take the red peaks as a model, the reverse scan of the 
voltammogram begins with a high concentration of benzoquinone which is 
reduced to hydroquinone as the potential decreases. The UV-Vis scans begins 
with a high absorbance due to the high concentration of benzoquinone, this peak 
slowly decreases as the concentration decreases during the reduction reaction.
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Vice versa with the green peaks, which show changes in concentration levels as 
the potential sweeps from -0.4 to 0.8 V.
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Figure 4-20: A voltammogram and UV-Vis scan illustrating the redox reaction and 
concentration changes of benzoquinone.
This UV-Vis-EC technique demonstrates the versatility of the CF material and the 
viability of the simple three electrode CF laminate composite strip to be used in 
complex clinical analysis.
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4.6 Conclusion
The expensive nature of glassy carbon combined with the difficulties in 
processing the material into a disposable format would clearly prevent its 
mainstream use in near patient testing contexts. The material should ideally 
possess similar sensitivity and resolution to that exhibited by the GC electrode 
but must be of a form that could be integrated into a disposable format. Modified 
CF laminates have been shown to facilitate the unambiguous analysis of urate 
within physiological fluids and the responses have been independently validated 
through inter-laboratory comparison. The material could be fashioned into a 
cheap, disposable format through the production of large area laminates within 
individual sensors arising through appropriate cutting of the composite sheet. As 
such, the approach could be a viable means through which point of care sensors 
could be produced. The electrode responses are superior to those obtained at 
commercial screen printed electrodes with behaviour characteristic of a glassy 
carbon substrate but significantly less expensive. The approach taken is generic 
and sufficiently transferable for the substrate and fabrication method to be 
considered for other sensing applications, including complex hyphenated 
techniques like EC-UV-Vis to probe redox properties of molecules which are 
important to the functioning of living cells e.g. quinones.
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5 Multianalysis Investigation with Uric Acid
Uric acid (UA) has a iong history in clinical analysis and has served as an 
important diagnostic in a number of contexts. An increasing interest in metabolic 
syndrome has led to urate being used in combination with a number of other 
biomarkers for the assessment of cardiovascular risk. This is particularly 
significant as it is slowly recognised as an invaluable secondary (if not primary) 
marker when monitoring conditions such as diabetes and heart disease rather 
than as an electrochemical interferent. This has resulted in the evolution of 
various strategies that can integrate the urate signal within the device 
architecture to assess a series of biomarkers with one test. The results presented 
in this chapter cover the investigation and development of a simple methodology 
for urate, ascorbate and glucose multianalysis combined with the carbon fibre 
(CF) strips technology.
Clinical investigations have revealed that urate is a key player in a number 
of metabolic processes that have considerable diagnostic significance [1]. While 
commonly regarded as an indicator of gout [2], current interest in metabolic 
syndrome has identified urate as a versatile handle through which the progress of 
cardiovascular [1-8], kidney diseases [9-13] and a number of diabetic 
complications can be gauged [14-16]. Using electrochemical techniques similar to 
the voltammetric techniques demonstrated previously, to separate UA from 
ascorbic acid (AA) it could be envisaged that this purine be monitored in a clinical 
environment as a biomarker in its own right for diabetic complications. Combining 
a simple technique with the CF strips would provide the foundations for point of
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care strips analogous to glucose testing. Another advantage of creating a model 
system for clinical testing with the CF prototype is that this model could be 
transferred to other systems.
The ability to separate out signals pertaining to ascorbate and urate within 
a single voltammetric scan already offers the possibility of multi-analyte 
screening. Therefore, it could be anticipated that the analysis of urate, in 
combination with other biomarkers, could allow a more rounded evaluation of 
physiological well-being. A key example would be the combined analysis of 
glucose and urate where the latter could provide an indication of the early onset 
of potential cardiovascular complications common to diabetics [14-16]. The 
practical exploitation of such will however be dependent upon the development of 
a methodology that can allow the concentrations of such species to be speedily 
evaluated. This could then be employed within the immediate clinical setting by 
the attendant biomedical staff where, at present, most investigations require 
referral of the blood sample to a central laboratory for analysis.
Developing a multianalyte sensor for pharmacological use would inevitably 
lead to the production of a biosensor where an enzyme is employed to aid in the 
unique detection in a complex electroactive mixture. There are different methods 
of monitoring a reaction where an enzyme is employed, for example with glucose 
either the consumption of oxygen or the production of peroxide can be monitored: 
p -  D-Glucose + 0 2 -> D-Gluconolactone + H2O2 
The oxygen electrode measures the diffusion flow of oxygen through the 
membrane. The current output of the electrode is a linear function of the oxygen 
tension.
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The hydrogen peroxide can be detected directly at the electrode [17,18]:
(3 -  D-Glucose + O2 —► D-Gluconolactone + H2O2 
H20 2 ^ 0 2 + 2H+ + 2e"
However, electrochemical techniques suffer interference from other physiological 
electroactive species due to the large overpotential required to oxidise the 
peroxide. Another problem is the progressive inactivation of glucose oxidase by 
the production of high levels of peroxide. These technical difficulties can be 
overcome by careful manipulation of the various parts that make up the device 
e.g. varying the immobilisation of the enzyme, changing the enzyme itself, 
introducing a mediator or changing the electrode material [19].
The majority of biosensing electrode designs in previous years have 
utilised amperometric methodologies so that an unambiguous peroxide signal 
can be recorded. The amperometric process has traditionally focused on the 
application of a single potential step to reduce or oxidise the peroxide. Given the 
possibility that clear separation of ascorbate and urate can be achieved at the CF 
substrate, a multiple step procedure could be employed where the potential is 
sequentially moved to positions where ascorbate, urate and finally peroxide 
oxidation (or indeed reduction) is initiated. The instrumental simplicity would be 
retained, as the underlying methodology is still a simple potential step technique - 
albeit operating several times.
The research presented herein is the developmental steps taken to 
provide a chronoamperometric method to carry out multianalysis of UA alongside 
glucose and AA. Preliminary research was carried out with a glassy carbon
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electrode (GCE): once there was an established methodology the process was 
transferred to the CF architecture. Further research was out carried with some 
mediators, which if involved in the multianalysis could potentially enhance routine 
analysis within a clinical environment.
5.1 Experimental Set-up
All reagents were of the highest grade available and used without further^ 
purification. Stock solutions of UA (typically 10 mM) were prepared in 0.1 M 
NaOH. All other solutions were prepared using Britton-Robinson buffer (acetic, 
boric and phosphoric acids - each at a concentration of 0.04 M) adjusted to pH 7 
through the addition of sodium hydroxide. Standard solutions were prepared in 
deionised water from an Elgastat (Elga, UK) water system and refrigerated when 
not in use. Toray carbon fibre cloth was purchased from E-Tek Inc (USA) and 
used as received. Lamination pouches (Rexel UK) were a commercial stationery 
variety with a film thickness of 75 pM each side. Copper shielding tape (100 pM 
thick, adhesive backed) was obtained from RS Electronics. Electrochemical 
measurements were conducted using a //Autolab type III computer controlled 
potentiostat (Eco-Chemie, Utrecht, The Netherlands) using a three electrode 
configuration consisting of a GCE or CF assembly working electrode, a platinum 
wire counter electrode and a Ag | AgCI (3M Cl ) half cell reference electrode (BAS 
Technicol, UK). A Thermo Unicam UV-Vis was used with Infinity Reagent ™ 
which was purchased from Thermo and stored at -5°C between sample 
preparations. The same procedure was used for the enzymatic analysis of UA as 
detailed previously in section 4.2.2.
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5.2 Potential Step Characterization
The initial characterization of both UA and AA was instigated with a single 
step calibration using chronoamperometry, with a GCE. The applied potential at 
which to oxidize each analyte was selected from the initial cyclic-voltammetric 
scans. Beginning with UA at 0.36 V, 50 pM additions were used to maintain 
representative concentrations. The calibration for UA shown here was taken at 
the 30-second point (LOD0.16pM), although successful calibrations were 
achieved after only 15 seconds (Figure 5-1).
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Figure 5-1: Single potential step at 0.36 V for UA with 50 pM additions. Inset: Calibration 
graph of conc. of UA vs. the current.
The AA calibration experiment was carried out at a potential of 0.20 V with 
equimolar concentration values to the UA experiment (Figure 5-2), again the 
calibration end point was at 30 seconds (LOD 0.12 pM).
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Figure 5-2: Single potential step at 0.20 V for AA with 50 pM additions. Inset: Calibration 
graph of conc. of AA vs. the current.
The two distinct potential steps were combined to determine whether two 
sequential calibrations could be quantified (Figure 5-3).
2.5
2.0  -
3- 6-
C
CD
—  125 (jM AA
—  300 nM UA
0.5
0.0 -
20 400 60 80
Time / s
Figure 5-3: Close up of double potential step at 0.20 V and 0.36 V for UA and AA in 10 mL 
BR at pH7 Insert: Complete scan.
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A typical chronoamperometric profile can be observed in the inset of 
Figure 5-3. Characteristically the first few seconds of the scan demonstrate a 
large spike in the current, which is attributed to the capacitance and does not 
provide reliable points for detection. The remaining Faradaic reaction can be 
tested after a few seconds. In general, any time less than 5 minutes is used for 
point of care testing, which was aimed for with the dual potential step. Initially, a 
300 pM of UA was added to the 10 mL BR (pH 7) then the scan was begun with 
the first potential step at 0.20 V for 50 seconds after which the second potential 
step was applied to oxidize the UA present in solution at 0.36 V. It was noted that 
a sharp increase in the current after the second step in Figure 5.3. Several 
aliquots of AA (25 pM) were added sequentially to the cell and a scan was run 
between each addition with a clear increase in the current on the first potential 
step with each addition. However, there is a drawback to using the dual potential 
step with a mixture of analytes. At the lowest applied potential only AA could be 
oxidized, but as the applied potential is stepped up 0.36 V it will oxidize UA and 
the high potential will oxidize some AA too. This can be observed from the 
chronoamperogram in Figure 5-3 where the AA additions have slightly increased 
the current on the second potential step. The effect of an analyte with a low 
oxidation potential on subsequent potential steps, in this case AA, was 
investigated further. It was fundamental to understand if this could be 
mathematically accounted for to allow the accurate concentration determination 
of each analyte in the multi step experiment. First of all a double potential step 
with only AA additions was investigated with an initial spike of 150 pM AA to keep
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the experiment as close to the real experiments as possible then 50 pM aliquots 
were added to the cell (Figure 5-4).
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Figure 5-4: AA effect using DP at 0.20 V and 0.36 V, with 50 pM additions of AA.
Visually, it was instantly clear that each AA addition led to an increase in current 
on the following potential step. This experiment was repeated in triplicate and the 
data was analysed by taking the current at 90s, which would mark the end of the 
UA pulse and dividing this value by the current at 60s and multiplying by 100%. 
This was carried out for each addition of AA to the experiment. The overall 
average increase with each addition was 24%, which suggests that if AA is 
quantified at the first potential step then it is possible to quantify the UA using the 
mathematical correction, at the second step.
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This increase will be utilized when quantifying the concentration of UA in 
any chronoamperometric experiment with both these analytes. Extra evidence 
was provided for the theory that the current increase on the second potential step 
is caused by the oxidation of labile AA when a test was carried out to see if 
additions of UA increase the current of the first potential step. Two calibration 
graphs were (of the single AA potential step) compared: the same method was 
used as the experiment in Figure 5-2. The key change was that the second 
calibration graph had an initial spike of 150 pM UA present (Figure 5-5).
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Figure 5-5: AA calibration graph with and without UA present.
There was a negligible effect from the UA when it was present during the AA 
calibration.
5.3 Standard Addition of UA and A A in Tissue Medium
Before running the clinical trial a standard addition calibration process was 
established using AA and UA additions with Dulbecco’s Tissue Medium, which is 
a synthetic physiological sample. The procedure involved 10 mL of tissue 
medium made up in Britton Robinson’s pH7 buffer that was initially added into the
Chapter 5: Multianalysis Investigation with Uric Acid 112
cell, after a blank scan an equimolar spike of 150 pM each of AA and UA was 
pipetted to the cell and stirred. A calibration with 50 pM increments of UA and AA 
respectively were then added to the cell for the calibration. Each potential step 
lasted 15 s to decrease the total analysis time. The first part of the calibration 
process for dual potential step again demonstrates that there is no reverse 
interference of the UA on the first potential step (Figure 5-6).
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Figure 5-6: Double potential step at 0.20 V and 0.36 V for AA and UA respectively with 5 mL 
tissue medium spike and 50 pM additions UA.
The percentage recovery was calculated from the known spike concentration 
prior to the correction discussed previously to account for the AA increasing the 
current on the second potential step the percentage recovery was 473.55 %, after 
the correction the recovery was 102.82 %. An example of the complex 
chronoamperogram that is created after the UA and AA calibration additions are 
shown in Figure 5-7.
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Figure 5-7: Standard Addition of AA & UA to 10 mL Tissue medium at pH7.
5.3.1 Interference Tests
Potential analytes, which are present in physiological samples and oxidize 
at similar potentials to AA and UA, were investigated using the dual potential step 
method to determine whether they would need to be eliminated from a 
multianalyte strip for AA and UA. Firstly, thiols were added in 50 pM increments 
up to 300 pM to a double potential step after spikes of AA and UA had been 
added. In the case of both cysteine and glutathione, the potential was not high 
enough for either to be oxidized and hence they did not interfere with his method. 
Paracetamol (PA) was investigated, as this is a common painkiller, which 
oxidizes at a similar potential to UA. Additions of PA to the dual potential step
100 pM Prespike of AA & UA 
150 pM Spike of AA & UA
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100 pM AA 
150 pM AA 
200 pM AA
50.0 pM UA 
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showed an incremental increase at the second potential step thus suggesting that 
PA would interfere with the analysis. This would need to be eliminated for clinical 
analysis either electrochemically at the strip or by ensuring that a patient has not 
consumed PA prior to testing (Figure 5-8).
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Figure 5-8: AA SP with AA addition to show influence of PA
5.4 Clinical Analysis
The aspiration of the dual potential step method is to combine it with a CF 
prototype for clinical analysis. It is therefore a necessity to demonstrate that UA 
can be quantified within a real sample using this process. The standard addition 
was adapted for use with sterilised urine from Sigma - Aldrich® which was 
dissolved in Britton Robinson’s pH7 buffer. The process involved taking 10 mL of 
blank buffer, which was pipetted into the cell. After a blank scan, an addition of
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450 |jL of the dissolved urine was added as a spike to the cell and stirred. A 
calibration series of 50 pM increments of UA was then compiled to complete the 
method. Each potential step lasted 15 s and was applied at the same potentials 
as before which was 0.20 V and 0.36 V respectively. The electrochemical 
calibration was baseline corrected using the AA mathematical correction outlined 
previously. The electrochemical method was then evaluated versus the UV-Vis 
technique (see section 4.2.2) with both techniques being analysed in triplicate.
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Figure 5-9: Double potential step at 0.20 V and 0.36 V for AA and UA respectively with 450 
pL urine spike and 5 pM additions of UA with the standard addition calibration graph.
UA Levels in Urine / pM RSD / %
UV-Vis
Spectrometry
493 0.88
Electrochemical 486
Number of replicates=3
2.60
Table 5-1: Comparison of UV-Vis spectrometry and Electrochemical analysis of UA in 
urine.
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The electrochemical chronoamperograms and calibration graphs are shown in 
Figure 5-9 and the results for the experiments are detailed in Table 5-1.
The results in Table 5-1 demonstrate that there is potential for this method to be 
used within the clinical environment, as it is comparable to UV-Vis, which it would 
eventually be evaluated against. In addition, the average recovery was between 
98 -  102%, further demonstrating the validity of this technique for clinical 
assessment.
5.5 Inclusion o f Glucose
After establishing that a dual potential step technique could be used to 
separate out two analytes, which oxidise at a similar potential, there was an 
opportunity to combine this method with the CF electrodes. There was the added 
challenge of expanding the technique to include a third potential step.
Glucose
Electrode
GO Gluconolactone
Signal
Figure 5-10: Schematic of the reaction between glucose and glucose oxidase (GO).
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Hydrogen peroxide was investigated, as discussed previously. Therefore, 
production of hydrogen peroxide could be used for the detection of glucose. The 
hydrogen peroxide is produced during the reaction of glucose with glucose 
oxidase (GO). The peroxide can then be detected at the electrode surface in a 
2H+, 2e' reaction (Figure 5-10). An investigation was carried out to determine 
whether a triple potential chronoamperometric technique would separate out AA, 
UA and hydrogen peroxide. Initially a triple potential step at 0.2, 0.3 and 0.8 V 
with additions of hydrogen peroxide and AA was assessed to ascertain the 
behaviour of the different analytes with this technique (Figure 5-11).
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Figure 5-11: Triple potential step AA and hydrogen peroxide additions at a GCE at 0.20, 
0.35 and 0.80 V.
When the first addition of H20 2 is added, there is no increase at 0.2 V or 0.3 V, 
but an observed signal at 0.8 V as expected. The AA addition then increases the
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current at all three potentials, Furthermore, a second addition of H20 2 again only 
increases on the third applied potential. This action of the two analytes was first 
observed with the double potential step method. If there is clear separation 
between any analytes within the sample cell then you will observe a current 
increase at the ascribed oxidation potential of each analyte. This signal causes 
an extra current increase on any subsequent higher potentials applied to the 
sample cell. As there is no current increase at 0.2 V when H20 2 is added, it 
confirms H20 2 does not interfere with AA detection using this process providing 
that there is no chemical interaction i.e. oxidation of AA by H20 2. UA and H20 2 
interactions were studied using the same process (Figure 5-12).
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Figure 5-12: Triple potential step with UA and H20 2 additions.
A similar pattern was observed with both analytes, when UA was added it 
increased the current at 0.3 V but no effect occurred at 0.2 V. The successive
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addition of H20 2, increased only the current at 0.8 V verifying that H20 2 does not 
interfere with the detection of UA and vice versa during the timescale of the 
experiment. These experiments suggest that a multipotential step experiment for 
multianalysis with AA, UA and H20 2 is viable. The ability to resolve the latter 
offers the possibility of combining the system with other enzyme systems.
To test the viability of the strip with H20 2 produced from the glucose GO 
reaction, a calibration graph with 83 pM additions of glucose to an enzyme 
solution was obtained with the amperometric method discussed previously 
(Figure 5-13). A successful calibration graph was produced at 0.8 V with a LOD 
of 3.00 pM).
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Figure 5-13: Triple Potential step calibration graph measuring H20 2 increase with glucose 
additions.
The success of the triple potential step experiments demonstrating the separation 
of the three analytes and then the glucose detection in an enzyme buffer,
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naturally led to the next step to combine the processes and show the clear 
separation of AA, UA and glucose. The three step calibration with 17 pM 
additions of AA, UA and 100 jiM of glucose to an enzyme solution was analysed 
with the CF prototype. Each addition of analyte was detected at its oxidation 
potential with a significant increase in current (Figure 5-14).
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Figure 5-14: Triple potential step of AA, UA and glucose additions at a CF at 0.20, 0.30 and 
0.80 V respectively.
5.6 Mediator Analysis
Although the detection of H20 2 utilising the triple potential step technique 
was successful, it does require a significantly high potential for detection. This is 
fine for buffer and enzyme solutions but real physiological matrices would contain
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other electroactive components including tryptophan, tyrosine and thiols, which 
could interfere with the peroxide signal. Unfortunately, because the oxidation 
potential signals overlap between these interfering analytes it is not currently 
viable to produce a method with a series of increasing potential steps; this could 
however, be a possibility for further work. Mediators can be used to overcome the 
high overpotential needed for glucose detection when monitoring hydrogen 
peroxide. They do this via a redox process. If they are present during the reaction 
between G O  and glucose, any G O red  can react with the mediator, which in turn 
is oxidised at the electrode surface (Figure 5-15):
(3-D-Glucose + GO(ox) — ► D- Gluconolactone + GO(REd)
G O (red) + 2 M e d ia to r+(ox) ^ G O (ox)+ 2M ed ia to r(R ED) + 2H+
2 M e d ia to r(RED) — > 2 M e d ia to r+(0x) + 2e
M RED G lucose
—« o
Q .
CD
2e M o x  GO red
Figure 5-15: Schematic of electron shuttling by a mediator.
G lucono lactone
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Traditionally a mediator with a very low oxidation potential, typically below 0.2 V 
is used, as this will avoid oxidising any other analytes thus overcoming 
interference. An option for this investigation is a twist on the traditional mediator; 
the twist is discovering a mediator with a higher oxidation potential than UA to 
avoid interfering with the UA and AA signals, but with a low enough oxidation 
potential to overcome interference from other analytes. Another challenge to 
overcome is the varying surface area of the CF strips, which is indicative of how 
the matting is manufactured; hence each strip has a different reaction area, which 
cannot be physically measured. A chemical internal standard could be used 
which is added at a known concentration and supplies an electrical signal. One 
possibility is to use the mediator as a dual ingredient; firstly as the detection 
system for glucose and secondly as an internal standard.
Ferrocene dicarboxylic acid ((Fc(COOH)2) contrasts the conventional 
approach to the mediator system because it oxidises at a high potential, 
rendering it useless for current commercial glucose monitoring. However, it has 
the characteristics required for this investigation as a mediator. Fc(COOH)2 was 
compared to an established mediator ferrocene carboxylic (Fc(COOH)). The 
redox reactions of both mediators were compared with cyclic voltammetry 
(Figure 5-16), Fc(COOH)2 has a reversible redox reaction with an oxidation 
potential at 0.44V.
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Figure 5-16: Cyclicvoltammograms of Fc(COOH) and (Fc(COOH)2 oxidation peaks.
The next step was to review the effect of the potential mediator in an enzyme 
system. A GCE rotating disk electrode (RDE) was utilized with 
chronoamperometry at 0.5 V, 25 mL of the enzyme mixture were pipetted and a 
baseline obtained, after 2 mins the Fc(COOH)2 was added to the solution then 
every 30s an aliquot of glucose was added (Figure 5-17).
20 -.
0.8mM additions of glucose
1mM of Ferrocenedicarboxylic Acid
120 200 300
Tim e / s
Figure 5-17: Chronoamperogram of glucose additions to Fc(COOH)2 and GO solution at 
RDE in pH7 buffer.
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The resulting current steps, which, increased with each addition demonstrate that 
this ferrocene is able to mediate glucose in the enzyme solution. Next it was 
important to determine whether this ferrocene would be successful as a mediator 
without interfering with the other biomarkers. Initially cyclic and square-wave 
voltammetry were used to investigate any electroactive interactions between UA 
and the ferrocene. Equimolar additions (133 pM) to buffer starting with AA, UA 
then Fc(COOH)2 were added to a cell to determine whether there would be clear 
separation between each oxidation peak (Figure 5-18).
  133uM Ferrocene dicarboxylic Acid addition
 133f.iM Uric Acid addition
  133f.iM Ascorbic Acid addition
UA60
Fc(COOH),
50
40
30
AA20
10
0
0.2 0.4 0.6 1.00.0 0.8- 0.2
Potential / V
Figure 5-18: Voltammogram showing sequential additions and oxidation peaks of AA, UA 
and (Fc(COOH)2 in pH7 buffer. Each analyte is present at 133 pM.
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This experiment demonstrated that there were no electrochemical interactions 
between the three analytes and there was no overlapping of the three peaks. To 
determine whether the triple potential step experiment could be adapted to the 
mediator a calibration plot was run with potential steps at 0.2, 0.3 and 0.5 V 
respectively with 15 ml_ of buffer and additions of 250 pM Fc(COOH)2 
(Figure 5-19).
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Figure 5-19: Calibration of (Fc(COOH)2 using the triple potential step technique in pH7 
buffer at CF strip.
The experiment demonstrated that this technique could be transposed to include 
the mediator with the third potential step at a lower potential of 0.5 V. To illustrate 
the effectiveness of a triple potential step technique to distinguish between the 
three analytes with a simple strip a series of single potential step experiments 
were tested. The first experiment had an applied potential of 0.2 V with 15 mL
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buffer, 75 pM additions of AA were added for a simple calibration graph. An 
addition of 200 pM of UA was added demonstrating that there was no current 
increase. Similarly, 100 pM of Fc(COOH)2 was added and it also had no effect on 
the current at this low potential which is only sufficient to oxidize AA (Figure 5- 
20).
Potential Step 1 
0.2 V
10 15
T im e / s
Ferrocene dicarboxylic Acid 
Uric Acid 
Ascorbic Acid 
Blank
50 100 150 200
Concentration AA / (jM
Figure 5-20: Single potential step at 0.2 V with calibration additions of AA at 75 pM, then 
UA at 200 pM and Fc(COOH)2at 100 pM in pH7 buffer.
This experiment process was repeated at 0.3 V with a UA calibration graph of 
75 pM additions of UA followed by 200 pM AA and 100 pM of Fc(COOH)2. As 
expected the additions of AA caused a large increase in current, however, the 
Fc(COOH)2 had no effect as the potential is still not high enough to oxidize it 
(Figure 5-21). Finally, a third experiment was run at 0.5V, 37.5pM aliquots of 
Fc(COOFI)2 were pipetted forming a calibration graph with subsequent additions 
of 200pM AA and 200pM UA thus demonstrating that both caused large 
increases in the current (Figure 5-22).
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Figure 5-21: Single potential step at 0.3 V with calibration additions of UA at 75 pM, then 
AA at 200 pM and Fc(COOH)2 at 100 pM in pH7 buffer.
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Figure 5-22: Single potential step at 0.5 V with calibration additions of Fc(COOH)2 at 
37.5 pM, then UA at 200 pM and AA at 200 pM in pH7 buffer.
The data from these three single potential step experiments provide further 
evidence that a triple potential step would be a successful method to use in 
determining their concentrations in a complex matrix.
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5.7 Conclusion
A dual potential step experiment using chronoamperometry as a method of 
separating and quantifying AA and UA was developed. This technique employs a 
simple electrochemical process where a potential step is applied over time to 
oxidize a particular analyte. This technique was validated versus UV-Vis 
spectrometry. The advantage of employing chronoamperometry is that it is 
already being used for clinical diagnostics so the technique could be transferred 
easily for clinical analysis.
This method was developed further to a three potential step technique, 
which was used to separate out AA, UA and H2O2 using the CF prototype strip. 
The ability to measure H2O2 opens up further possibilities of using different 
oxidase enzyme systems for other biomarker systems. This was demonstrated 
with GO but could be applied to other systems such as cholesterol or lactate 
oxidases. Along with the developed potential step method, fundamental research 
into a mediator to decrease testing time was investigated - this technology has 
set the foundations for a multianalyte device for near patient testing of UA 
alongside glucose and AA.
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6 Conclusions and Further Work
6.1 Conclusion
Urate has previously been passed over as a mere electroanalytical 
interferent, since it has a low oxidation potential and is ubiquitous in clinical 
samples. Recent research has shown the tide is turning as urate is 
established as a biomarker for several significant conditions, including 
pre-eclampsia, gout, cardiovascular and kidney disease, many of which are 
also linked to diabetes. Although the importance of urate measurements has 
been established it is clear that the concentration of a single type of biomarker 
can be influenced by a number of factors and that the subsequent ambiguity 
may actually lessen the diagnostic value of the initial test. There is therefore a 
strong need within clinical settings for the provision of devices that can 
facilitate the determination of a range of biomarkers in place of the tests that 
would be returned from a centralised biochemistry laboratory acting on a 
conventional blood test. The additional information essentially allows the 
clinician to identify the underlying condition at hand and allow a more targeted 
assessment of the disease progression or treatment. A prime example are 
some forms of pre-eclampsia where there may be little physical symptoms to 
guide an initial / early consultation but where the results of a urate test may 
reveal cause for concern. The ability to provide an immediate blood screen 
response within a general practitioner’s surgery would obviously be the 
preferred option. Uric acid (UA) provides an excellent opportunity to widen the 
net on point of care testing, due to its requirement as a biomarker and its 
strong electrochemical signal. The key in creating an original system of
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detection for urate would be to develop a transferable prototype, which could 
be used to probe other biochemical systems, resulting in a biomarker toolkit 
for surgery based testing. Therefore, any materials and techniques would 
need to be relatively cheap, disposable and easily maintained whilst any 
method would need to be robust to stand up to the rigours of clinical testing.
6.1.1 Characterisation of Uric Acid
The characterisation of UA’s strong adsorption oxidation peak was 
proven which is also observed with other purines including precursors like 
xanthine and hypoxanthine and DNA bases, adenine and guanine. The 
investigation of interactions with other electro species that would be present in 
physiological fluids led to a novel method of tagging, which was first illustrated 
with UA and cysteine. Using nucleophilic addition it was possible to monitor 
UA via the conjugate peak in the presence of ascorbic acid (AA). This 
technique was transferred to guanine, which also displayed clear tagging. 
Similarly, this method for separation via purine tagging, could aid in our 
understanding of the in-vivo regulation of anti-oxidant thiol concentrations as 
the oxidation of the purine may clearly induce the depletion of the former. 
Whilst the nucleophilic tagging of the purines is a successful and innovative 
procedure, which could be exploited for the detection of urate, this process 
would more than likely be based in a laboratory rather than in diagnostic 
testing.
6.1.2 Prototype Biosensor
Current technologies use screen printed technology, which is versatile 
and adequate for monitoring analytes at millimolar concentrations, for example
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glucose. However, this material is unsuitable for screening analytes at 
micromolar concentrations. The voltammetric experiments of UA and AA with 
a screen printed electrode (SPE) would not allow precise measurements for 
the determination of both analytes.
Carbon fibre was tested as an alternative material to screen printed 
electrodes. It provides all of the necessary characteristics required in a 
diagnostic strip, which include highly conductive, clinically viable, safe and 
easy to manipulate for the creation of a strip. Two designs were created in 
laminate casing to demonstrate the micro and macro capabilities of the 
material. The strips were electrochemically pre-treated to improve the 
response to both AA and UA, the resulting strips led to clear separation of the 
two oxidation peaks. The strips were tested for their applicability to 
physiological testing during a clinical trial where serum samples from various 
volunteers were analysed and validated versus the standard method of 
assessment using UV-Vis spectrometry. The disposable strips compared 
favourably with the independent laboratory results. The basic fabrication of 
these sensors is robust and would be ideal for proof of concept studies, 
particularly within biomedical research.
6.1.3 Multianalyte Method Development
The primary aim of this research was to produce a technique for 
decentralised testing of UA. This would necessitate a simple portable method 
of detection. Current portable sensors employ a chronoamperometric 
technique. This involves simple technology, which is easily miniaturised. To 
advance the current method of a single potential applied to oxidise the whole 
sample, this was developed to enable a series of increasing potential steps to
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be applied to a single sample. The simplicity of this technique is that current 
technology could be adapted thus maintaining the versatility of current 
diagnostics, it also allows complex multianalysis to be carried out on a single 
sample obtained from a patient, thus improving patient care.
A potential step method was developed for the analysis of both UA and 
AA, which was validated versus UV-Vis spectrometry with clinical samples. 
This method was then expanded to include hydrogen peroxide (H2O2). Initially, 
the H2O2 was added manually. Establishing the technique with H2O2 meant 
that other analytes requiring an oxidase enzyme could theoretically be 
detected. The translation of this theory was tested, by using a glucose oxidase 
mixture to detect glucose additions. This technique was able to separate out 
three analytes, which historically cause interference with one another but are 
each important biomarkers, they are AA, UA and glucose.
In conclusion, a novel decentralised test for UA was developed with a 
prototype for a disposable biosensor employed with a transferable sequential 
potential step method, which demonstrated multianalysis of three key 
biomarkers. Both the strip and the method were assessed for their clinical 
viability versus the standard UV-Vis spectrometry technique for UA detection.
6.2 Further Work
The viability of the prototype CF electrode was tested during a clinical 
trial, whilst the evaluation showed the potential for this strip in biosensing. It 
would be of interest to carry out further investigations into an internal 
standard. The presence of an internal standard would overcome any 
differences inherent between strips due to the nature of the CF matting. It 
would also overcome the need for any UA calibration additions thereby
Chapter 6: Conclusions and Further Work 134
speeding up the method of detection. Initial exploratory experiments were 
performed using the mediator ferrocene dicarboxylic acid, but this would need 
to be validated using clinical samples versus an established technique.
A triple multi potential step technique was successfully used to separate 
out UA, AA and glucose. Based on the dual potential step it could be 
rationalised that the more complex method could be used with physiological 
samples, however, it was beyond the range of the present study to fully 
examine this issue but may be useful to examine in future.
The CF strips vastly improved the detection of UA and AA, however, 
each sample was based within an electrode cell. Future work could include 
developing the ring electrode to a sample ‘well’ for UA detection in a micro litre 
sample, similar to that used in current decentralised testing.
The areas of examination in the current study continue to be of both 
commercial and academic interest and studies will undoubtedly shed light on 
some if not all of these areas in the future.
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understanding that the Ethical Guidelines for Teaching and Research are-observed. For 
your information, and future reference, these Guidelines can be downloaded from, the 
C?nmTnlttee*s website at htto://www.sunev a^c.nk/Surrev/AGE/.
The Committee requ ires that the handling of blood must be earned out in accordance with 
the University Policy on the Donation and Use- of Human Specimens hr Teaching and 
Research (March. 1998 -  SP/03/98} and I enclose a copy of that Policy for your 
information. The Committee also requires that the Consent Form for the Donation of 
Blood conforms wife that produced by foe University .as included in the attached policy 
document. . . . .
This letter of approval relates only to the study specified in your research protocol 
(ACE/2G02/65/SBLS) -FastTrack The Committee should be notified of any changes to 
foe proposal, any adverse rpacSqns; and if foe study is terminated earlier than expected, 
with reasons.
Date of-approval by the Advisory Committee on Ethics: 23 August 2002
Date of expiry of approval by the Advisory Committee on Ethics: 22 August 2007
Please inform me when the research has'been completed,
Yours sincerely
Catherine Ashbee (Mrs)
Secretary, University Advisory Committee on Ethics
cc: Chairman, ACE
Dr J Davis, Principal Investigator, Dept of Chemistry
. SOOTH WEST SURREY LOCAJURESEARCH ETHICS COMMITTEE
. Education .Centre,
The Royaj Surrey. County Hospital, Egerton Road 
‘ • Gailtffordj Surrey <502 TXX
TeL* #1483371122 exi4382 * Pax: 01483 303691 
E mail: joTin.feerstake@ioya|5U^rey.nfjs,uk
Chairman: Professor D L Riisseil-Johes MD FRCP . Co-ordinator: Mr 3 Kerslake
■ Please quote •
OurRef: EC55/G2 . '
24 July 2002
Dr C Livingstone 
Consultant Chemical Pathologist
Clinical Investigation Unit . .
Royal Surrey County Hospital
GUILDFORD * ■ .
GU2 5XX
Dear Dr Livingstone
Development of thiol-specific chemical sensors for the near-patient monitoring of 
oxidative stress ,
I am pleased to be able to inform you that at its meeting held on 23 July 2002 the Ethics 
Committee approved the above study.
The Committee  ^decision was based on. its review of the -following documents:
• * .t ,
(i) The South West Surrey LREC Application Form which you signed on 25 June 
2002.
(ii) The Patient Information Sheet, dated June2002.
(iii) The Patient Consent Form dated June 2002.- .
(iv) The Subject Information Sheet dated June2002.
(v) The Subject Consent. Form dated June 2002.
The Committee’s approval is subject to the following conditions:
(i) No changes should be made to the documents listed above or the procedures set 
• •. . out in them without prior written approval of the Committee.
(ii) The project must be started within three years of the date on which the Committee 
approved the study, If the study is delayed it is your responsibility to ensure that 
due account is taken of any new research information or developments which
- might affect the design Or conduct of the study. Any amendments arising from this 
would need to be approved by the Committee before commencement of the study.
{Hi) The Committee should be provided with progress reports on the study at- annual
intervals and a copy of 4 report on the cmteome of the study ox a copy of any 
published document
'Yarns sincerely
J C$SN KERSLAKE 
Co-ordinator
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
